|
ý
|
QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
|
94-2359345
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification Number)
|
|
|
|
3100 Hansen Way,
Palo Alto, California
|
|
94304-1038
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Large Accelerated filer
|
|
x
|
|
Accelerated filer
|
|
o
|
Non-Accelerated filer
|
|
o
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
o
|
Emerging growth company
|
|
o
|
|
|
|
|
|
Part I.
|
|
||
|
|
|
|
Item 1.
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
|
|
Item 2.
|
|
||
|
|
|
|
Item 3.
|
|
||
|
|
|
|
Item 4.
|
|
||
|
|
|
|
Part II.
|
|
||
|
|
|
|
Item 1.
|
|
||
|
|
|
|
Item 1A.
|
|
||
|
|
|
|
Item 2.
|
|
||
|
|
|
|
Item 3.
|
|
||
|
|
|
|
Item 4.
|
|
||
|
|
|
|
Item 5.
|
|
||
|
|
|
|
Item 6.
|
|
||
|
|
|
|
|
Three Months Ended
|
||||||
|
December 29,
|
|
December 30,
|
||||
(In millions, except per share amounts)
|
2017
|
|
2016
|
||||
Revenues:
|
|
|
|
||||
Product
|
$
|
365.6
|
|
|
$
|
309.2
|
|
Service
|
312.9
|
|
|
292.3
|
|
||
Total revenues
|
678.5
|
|
|
601.5
|
|
||
Cost of revenues:
|
|
|
|
||||
Product
|
223.9
|
|
|
206.2
|
|
||
Service
|
151.8
|
|
|
128.3
|
|
||
Total cost of revenues
|
375.7
|
|
|
334.5
|
|
||
Gross margin
|
302.8
|
|
|
267.0
|
|
||
Operating expenses:
|
|
|
|
||||
Research and development
|
55.9
|
|
|
49.9
|
|
||
Selling, general and administrative
|
125.5
|
|
|
161.4
|
|
||
Impairment charges
|
—
|
|
|
38.3
|
|
||
Total operating expenses
|
181.4
|
|
|
249.6
|
|
||
Operating earnings
|
121.4
|
|
|
17.4
|
|
||
Interest income
|
3.2
|
|
|
4.8
|
|
||
Interest expense
|
(2.1
|
)
|
|
(2.9
|
)
|
||
Earnings from continuing operations before taxes
|
122.5
|
|
|
19.3
|
|
||
Taxes on earnings
|
234.7
|
|
|
11.3
|
|
||
Net earnings (loss) from continuing operations
|
(112.2
|
)
|
|
8.0
|
|
||
Net earnings from discontinued operations
|
—
|
|
|
6.5
|
|
||
Net earnings (loss)
|
(112.2
|
)
|
|
14.5
|
|
||
Less: Net earnings attributable to noncontrolling interests
|
0.1
|
|
|
0.6
|
|
||
Net earnings (loss) attributable to Varian
|
$
|
(112.3
|
)
|
|
$
|
13.9
|
|
|
|
|
|
||||
Net earnings (loss) per share - basic
|
|
|
|
||||
Continuing operations
|
$
|
(1.22
|
)
|
|
$
|
0.08
|
|
Discontinued operations
|
—
|
|
|
0.07
|
|
||
Net earnings (loss) per share - basic
|
$
|
(1.22
|
)
|
|
$
|
0.15
|
|
|
|
|
|
||||
Net earnings (loss) per share - diluted
|
|
|
|
||||
Continuing operations
|
$
|
(1.22
|
)
|
|
$
|
0.08
|
|
Discontinued operations
|
—
|
|
|
0.07
|
|
||
Net earnings (loss) per share - diluted
|
$
|
(1.22
|
)
|
|
$
|
0.15
|
|
|
|
|
|
||||
Shares used in the calculation of net earnings per share:
|
|
|
|
||||
Weighted average shares outstanding - basic
|
91.6
|
|
|
93.5
|
|
||
Weighted average shares outstanding - diluted
|
91.6
|
|
|
94.2
|
|
|
Three Months Ended
|
||||||
|
December 29,
|
|
December 30,
|
||||
(In millions)
|
2017
|
|
2016
|
||||
Net earnings (loss)
|
$
|
(112.2
|
)
|
|
$
|
14.5
|
|
Other comprehensive earnings (loss), net of tax:
|
|
|
|
||||
Defined benefit pension and post-retirement benefit plans:
|
|
|
|
||||
Amortization of prior service cost included in net periodic benefit cost, net of tax benefit of $0.1 and $0.1
|
(0.2
|
)
|
|
(0.1
|
)
|
||
Amortization of net actuarial loss included in net periodic benefit cost, net of tax expense of ($0.2) and ($0.2)
|
0.5
|
|
|
0.9
|
|
||
|
0.3
|
|
|
0.8
|
|
||
Derivative instruments:
|
|
|
|
||||
Change in unrealized loss, net of tax benefit of $0.1 and $0.0
|
(0.2
|
)
|
|
—
|
|
||
Reclassification adjustments, net of tax expense of $0.0 and $0.0
|
(0.1
|
)
|
|
—
|
|
||
|
(0.3
|
)
|
|
—
|
|
||
Currency translation adjustment
|
3.1
|
|
|
(13.1
|
)
|
||
Other comprehensive earnings (loss)
|
3.1
|
|
|
(12.3
|
)
|
||
Comprehensive earnings (loss)
|
(109.1
|
)
|
|
2.2
|
|
||
Less: Comprehensive earnings attributable to noncontrolling interests
|
0.1
|
|
|
0.6
|
|
||
Comprehensive earnings (loss) attributable to Varian
|
$
|
(109.2
|
)
|
|
$
|
1.6
|
|
|
December 29,
|
|
September 29,
|
||||
(In millions, except par values)
|
2017
|
|
2017
|
||||
Assets
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
822.6
|
|
|
$
|
716.2
|
|
Trade and unbilled receivables, net of allowance for doubtful accounts of $42.6 at December 29, 2017 and $45.9 at September 29, 2017
|
880.1
|
|
|
961.5
|
|
||
Inventories
|
431.4
|
|
|
417.7
|
|
||
Prepaid expenses and other current assets
|
206.2
|
|
|
190.3
|
|
||
Current assets of discontinued operations
|
11.3
|
|
|
11.1
|
|
||
Total current assets
|
2,351.6
|
|
|
2,296.8
|
|
||
Property, plant and equipment, net
|
250.4
|
|
|
255.3
|
|
||
Goodwill
|
223.4
|
|
|
222.6
|
|
||
Intangible assets
|
65.6
|
|
|
71.6
|
|
||
Deferred tax assets
|
112.8
|
|
|
147.3
|
|
||
Other assets
|
296.0
|
|
|
300.8
|
|
||
Total assets
|
$
|
3,299.8
|
|
|
$
|
3,294.4
|
|
Liabilities and Equity
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Accounts payable
|
$
|
152.0
|
|
|
$
|
162.3
|
|
Accrued liabilities
|
350.0
|
|
|
374.9
|
|
||
Deferred revenues
|
772.3
|
|
|
755.4
|
|
||
Short-term borrowings
|
340.0
|
|
|
350.0
|
|
||
Current liabilities of discontinued operations
|
2.1
|
|
|
2.5
|
|
||
Total current liabilities
|
1,616.4
|
|
|
1,645.1
|
|
||
Other long-term liabilities
|
292.4
|
|
|
127.4
|
|
||
Total liabilities
|
1,908.8
|
|
|
1,772.5
|
|
||
Commitments and contingencies (Note 9)
|
|
|
|
||||
Equity:
|
|
|
|
||||
Varian stockholders' equity:
|
|
|
|
||||
Preferred stock of $1 par value: 1.0 shares authorized; none issued and outstanding
|
—
|
|
|
—
|
|
||
Common stock of $1 par value: 189.0 shares authorized; 91.6 and 91.7 shares issued and outstanding at December 29, 2017, and at September 29, 2017, respectively
|
91.6
|
|
|
91.7
|
|
||
Capital in excess of par value
|
740.5
|
|
|
716.1
|
|
||
Retained earnings
|
620.2
|
|
|
778.6
|
|
||
Accumulated other comprehensive loss
|
(65.7
|
)
|
|
(68.8
|
)
|
||
Total Varian stockholders' equity
|
1,386.6
|
|
|
1,517.6
|
|
||
Noncontrolling interests
|
4.4
|
|
|
4.3
|
|
||
Total equity
|
1,391.0
|
|
|
1,521.9
|
|
||
Total liabilities and equity
|
$
|
3,299.8
|
|
|
$
|
3,294.4
|
|
|
Three Months Ended
|
||||||
|
December 29,
|
|
December 30,
|
||||
(In millions)
|
2017
|
|
2016
|
||||
Cash flows from operating activities:
|
|
|
|
||||
Net earnings (loss)
|
$
|
(112.2
|
)
|
|
$
|
14.5
|
|
Adjustments to reconcile net earnings to net cash provided by operating activities:
|
|
|
|
|
|
||
Share-based compensation expense
|
10.7
|
|
|
11.5
|
|
||
Depreciation
|
12.8
|
|
|
17.2
|
|
||
Amortization of intangible assets
|
6.3
|
|
|
5.1
|
|
||
Deferred taxes
|
44.9
|
|
|
(20.9
|
)
|
||
Provision for doubtful accounts receivable
|
1.5
|
|
|
38.1
|
|
||
Impairment charges
|
—
|
|
|
38.3
|
|
||
Other, net
|
(0.8
|
)
|
|
(0.6
|
)
|
||
Changes in assets and liabilities:
|
|
|
|
|
|||
Trade and unbilled receivables
|
65.9
|
|
|
32.4
|
|
||
Inventories
|
(11.7
|
)
|
|
(30.1
|
)
|
||
Prepaid expenses and other assets
|
28.2
|
|
|
(10.1
|
)
|
||
Accounts payable
|
(10.3
|
)
|
|
(20.7
|
)
|
||
Accrued liabilities and other long-term liabilities
|
125.1
|
|
|
(20.3
|
)
|
||
Deferred revenues
|
18.6
|
|
|
27.8
|
|
||
Net cash provided by operating activities
|
179.0
|
|
|
82.2
|
|
||
Cash flows from investing activities:
|
|
|
|
|
|
||
Purchases of property, plant and equipment
|
(9.3
|
)
|
|
(17.2
|
)
|
||
Issuance of notes receivable
|
—
|
|
|
(11.4
|
)
|
||
Investment in available-for-sale securities
|
(6.0
|
)
|
|
(0.6
|
)
|
||
Loans to CPTC
|
(4.6
|
)
|
|
—
|
|
||
Escrow deposit
|
(2.6
|
)
|
|
—
|
|
||
Investment in privately-held company
|
(2.5
|
)
|
|
—
|
|
||
Amounts paid to deferred compensation plan trust account
|
(1.3
|
)
|
|
(3.4
|
)
|
||
Principal payments on notes receivable
|
0.5
|
|
|
—
|
|
||
Other, net
|
—
|
|
|
0.8
|
|
||
Net cash used in investing activities
|
(25.8
|
)
|
|
(31.8
|
)
|
||
Cash flows from financing activities:
|
|
|
|
|
|
||
Repurchases of common stock
|
(56.7
|
)
|
|
(49.5
|
)
|
||
Proceeds from issuance of common stock to employees
|
24.2
|
|
|
16.1
|
|
||
Employees' taxes withheld and paid for restricted stock and restricted stock units
|
(0.3
|
)
|
|
(1.2
|
)
|
||
Borrowings under credit facility agreement
|
166.4
|
|
|
10.0
|
|
||
Repayments under credit facility agreement
|
(166.4
|
)
|
|
(10.0
|
)
|
||
Net (repayments) borrowings under the credit facility agreements with maturities less than 90 days
|
(10.0
|
)
|
|
(55.0
|
)
|
||
Net cash used in financing activities
|
(42.8
|
)
|
|
(89.6
|
)
|
||
Effects of exchange rate changes on cash and cash equivalents
|
(4.0
|
)
|
|
10.4
|
|
||
Net increase (decrease) in cash and cash equivalents
|
106.4
|
|
|
(28.8
|
)
|
||
Cash and cash equivalents at beginning of period *
|
716.2
|
|
|
843.5
|
|
||
Cash and cash equivalents at end of period *
|
$
|
822.6
|
|
|
$
|
814.7
|
|
|
Fiscal years of revenue recognition
|
||||||||||||||
(In millions)
|
2018
|
|
2019
|
|
2020
|
|
Thereafter
|
||||||||
Unfulfilled Performance Obligations
|
$
|
1,588.2
|
|
|
$
|
1,857.4
|
|
|
$
|
697.4
|
|
|
$
|
1,384.6
|
|
|
Three Months Ended
|
||||||||||
|
December 30, 2016
|
||||||||||
(In millions, except per share amounts)
|
As Previously Reported
|
|
Adjustments
|
|
As Adjusted
|
||||||
Revenues:
|
|
|
|
|
|
||||||
Product
|
$
|
343.6
|
|
|
$
|
(34.4
|
)
|
|
$
|
309.2
|
|
Service
|
268.2
|
|
|
24.1
|
|
|
292.3
|
|
|||
Total revenues
|
611.8
|
|
|
(10.3
|
)
|
|
601.5
|
|
|||
Cost of revenues:
|
|
|
|
|
|
||||||
Product
|
224.4
|
|
|
(18.2
|
)
|
|
206.2
|
|
|||
Service
|
111.7
|
|
|
16.6
|
|
|
128.3
|
|
|||
Total cost of revenues
|
336.1
|
|
|
(1.6
|
)
|
|
334.5
|
|
|||
Gross margin
|
275.7
|
|
|
(8.7
|
)
|
|
267.0
|
|
|||
Earnings from continuing operations before taxes
|
28.0
|
|
|
(8.7
|
)
|
|
19.3
|
|
|||
Taxes on earnings
|
13.5
|
|
|
(2.2
|
)
|
|
11.3
|
|
|||
Net earnings from continuing operations
|
14.5
|
|
|
(6.5
|
)
|
|
8.0
|
|
|||
Net earnings from discontinued operations
|
6.5
|
|
|
—
|
|
|
6.5
|
|
|||
Net earnings
|
$
|
21.0
|
|
|
$
|
(6.5
|
)
|
|
$
|
14.5
|
|
Net earnings attributable to Varian
|
$
|
20.4
|
|
|
$
|
(6.5
|
)
|
|
$
|
13.9
|
|
|
|
|
|
|
|
||||||
Diluted net earnings per share from continuing operations attributable to Varian
|
$
|
0.15
|
|
|
$
|
(0.07
|
)
|
|
$
|
0.08
|
|
|
September 29, 2017
|
||||||||||
(In millions)
|
As Previously Reported
|
|
Adjustments
|
|
As Adjusted
|
||||||
Assets:
|
|
|
|
|
|
||||||
Trade and unbilled receivables, net
|
$
|
823.5
|
|
|
$
|
138.0
|
|
|
$
|
961.5
|
|
Inventories
|
439.7
|
|
|
(22.0
|
)
|
|
417.7
|
|
|||
Prepaid expenses and other current assets
|
199.8
|
|
|
(9.5
|
)
|
|
190.3
|
|
|||
Deferred tax assets
|
138.8
|
|
|
8.5
|
|
|
147.3
|
|
|||
|
|
|
|
|
|
||||||
Liabilities and Equity:
|
|
|
|
|
|
||||||
Accrued liabilities
|
394.7
|
|
|
(19.8
|
)
|
|
374.9
|
|
|||
Deferred revenues
|
640.6
|
|
|
114.8
|
|
|
755.4
|
|
|||
Other long-term liabilities
|
130.0
|
|
|
(2.6
|
)
|
|
127.4
|
|
|||
Retained earnings
|
756.0
|
|
|
22.6
|
|
|
778.6
|
|
|
Three Months Ended
(1)
|
||
(In millions)
|
December 30,
2016 |
||
Revenues
|
$
|
151.5
|
|
Cost of revenues
|
92.7
|
|
|
Gross margin
|
58.8
|
|
|
Operating expenses
(2)
|
46.4
|
|
|
Operating earnings
|
12.4
|
|
|
Taxes on earnings
|
5.9
|
|
|
Net earnings from discontinued operations
|
6.5
|
|
|
Less: Net earnings from discontinued operations attributable to noncontrolling interests
|
0.1
|
|
|
Net earnings from discontinued operations attributable to Varian
|
$
|
6.4
|
|
(1)
|
There was no activity in net earnings from discontinued operations during the three months ended
December 29, 2017
.
|
(2)
|
Operating expenses included separation costs of
$14.9 million
during the three months ended
December 30, 2016
. Separation costs include expenses for transaction advisory services, consulting services, restructuring and other expenses.
|
(In millions)
|
December 29,
2017 |
|
September 29,
2017 |
||||
Assets:
|
|
|
|
||||
Trade accounts receivable, net
|
$
|
9.0
|
|
|
$
|
8.1
|
|
Inventories
|
2.2
|
|
|
2.9
|
|
||
Prepaid expenses and other current assets
|
0.1
|
|
|
0.1
|
|
||
Current assets of discontinued operations
|
11.3
|
|
|
11.1
|
|
||
Total assets of discontinued operations
|
$
|
11.3
|
|
|
$
|
11.1
|
|
Liabilities:
|
|
|
|
||||
Accounts payable
|
$
|
1.2
|
|
|
$
|
2.0
|
|
Accrued liabilities
|
0.9
|
|
|
0.5
|
|
||
Current liabilities of discontinued operations
|
2.1
|
|
|
2.5
|
|
||
Total liabilities of discontinued operations
|
$
|
2.1
|
|
|
$
|
2.5
|
|
|
Three Months Ended
(1)
|
||
(In millions)
|
December 30,
2016 |
||
Operating activities:
|
|
||
Share-based compensation expense
|
$
|
1.3
|
|
Depreciation expense
|
3.3
|
|
|
Amortization expense
|
1.3
|
|
|
Investing activities:
|
|
||
Purchases of property, plant and equipment
|
(5.0
|
)
|
(1)
|
There was no cash flow activity from discontinued operations during the three months ended
December 29, 2017
.
|
(In millions)
|
December 29,
2017 |
|
September 29,
2017 |
||||
Unbilled receivables - current
|
$
|
269.5
|
|
|
$
|
259.1
|
|
Unbilled receivables - long-term
(1)
|
29.0
|
|
|
10.9
|
|
||
Deferred revenues - current
|
(772.3
|
)
|
|
(755.4
|
)
|
||
Deferred revenues - long-term
(2)
|
(8.8
|
)
|
|
(7.2
|
)
|
||
Total net unbilled receivables (deferred revenues)
|
$
|
(482.6
|
)
|
|
$
|
(492.6
|
)
|
(1)
|
Included in other assets on the Company's Condensed Consolidated Balance Sheets.
|
(2)
|
Included in other long-term liabilities on the Company's Condensed Consolidated Balance Sheets.
|
(In millions)
|
December 29,
2017 |
|
September 29,
2017 |
||||
Raw materials and parts
|
$
|
319.8
|
|
|
$
|
296.5
|
|
Work-in-process
|
47.6
|
|
|
47.7
|
|
||
Finished goods
|
64.0
|
|
|
73.5
|
|
||
Total inventories
|
$
|
431.4
|
|
|
$
|
417.7
|
|
|
December 29, 2017
|
||||||||||||||
(In millions)
|
Amortized Cost
|
|
Gross Unrealized Gains
|
|
Gross Unrealized Losses
|
|
Fair Value
|
||||||||
DRTC securities
(1)
|
$
|
8.0
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
8.0
|
|
APTC securities
(1)
|
6.0
|
|
|
—
|
|
|
—
|
|
|
6.0
|
|
||||
GPTC securities
(2)
|
4.5
|
|
|
—
|
|
|
—
|
|
|
4.5
|
|
||||
Total available-for-sale securities
|
$
|
18.5
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
18.5
|
|
|
September 29, 2017
|
||||||||||||||
(In millions)
|
Amortized Cost
|
|
Gross Unrealized Gains
|
|
Gross Unrealized Losses
|
|
Fair Value
|
||||||||
Original CPTC loans
(2)
|
$
|
47.4
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
47.4
|
|
DRTC securities
(2)
|
8.0
|
|
|
—
|
|
|
—
|
|
|
8.0
|
|
||||
GPTC securities
(2)
|
4.4
|
|
|
—
|
|
|
—
|
|
|
4.4
|
|
||||
Total available-for-sale securities
|
$
|
59.8
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
59.8
|
|
(1)
|
Included in prepaid and other current assets on the Company's Condensed Consolidated Balance Sheets because the Company has the ability and intent to sell these securities in the next twelve months. Subsequent to December 29, 2017, the Company sold its DRTC securities.
|
(2)
|
Included in other assets on the Company's Condensed Consolidated Balance Sheets because the maturity dates are greater than one year and the Company does not have the intent and ability to collect or sell all or a portion of its loans or securities in the next twelve months.
|
(In millions)
|
December 29,
2017 |
|
September 29,
2017 |
||||
Long-term income taxes payable
|
$
|
203.0
|
|
|
$
|
48.6
|
|
Deferred income taxes
|
27.3
|
|
|
17.1
|
|
||
Other
|
62.1
|
|
|
61.7
|
|
||
Total other long-term liabilities
|
$
|
292.4
|
|
|
$
|
127.4
|
|
|
|
Fair Value Measurement Using
|
||||||||||||||
|
|
Quoted Prices in
Active Markets for Identical Instruments |
|
Significant
Other Observable Inputs |
|
Significant
Unobservable Inputs |
|
Total
|
||||||||
Type of Instruments
|
|
(Level 1)
|
|
(Level 2)
|
|
(Level 3)
|
|
Balance
|
||||||||
(In millions)
|
|
|
|
|
|
|
|
|
||||||||
Assets at December 29, 2017:
|
|
|
|
|
|
|
|
|
||||||||
Available-for-sale securities:
|
|
|
|
|
|
|
|
|
||||||||
DRTC securities
|
|
$
|
—
|
|
|
$
|
8.0
|
|
|
$
|
—
|
|
|
$
|
8.0
|
|
APTC securities
|
|
—
|
|
|
6.0
|
|
|
—
|
|
|
6.0
|
|
||||
GPTC securities
|
|
—
|
|
|
4.5
|
|
|
—
|
|
|
4.5
|
|
||||
Total assets measured at fair value
|
|
$
|
—
|
|
|
$
|
18.5
|
|
|
$
|
—
|
|
|
$
|
18.5
|
|
|
|
|
|
|
|
|
|
|
||||||||
Liabilities at December 29, 2017:
|
|
|
|
|
|
|
|
|
||||||||
Derivative liabilities:
|
|
$
|
—
|
|
|
$
|
(0.4
|
)
|
|
$
|
—
|
|
|
$
|
(0.4
|
)
|
Total liabilities measured at fair value
|
|
$
|
—
|
|
|
$
|
(0.4
|
)
|
|
$
|
—
|
|
|
$
|
(0.4
|
)
|
|
|
|
|
|
|
|
|
|
||||||||
Assets at September 29, 2017:
|
|
|
|
|
|
|
|
|
||||||||
Available-for-sale securities:
|
|
|
|
|
|
|
|
|
||||||||
Original CPTC loans
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
47.4
|
|
|
$
|
47.4
|
|
DRTC securities
|
|
—
|
|
|
8.0
|
|
|
—
|
|
|
8.0
|
|
||||
GPTC securities
|
|
—
|
|
|
4.4
|
|
|
—
|
|
|
4.4
|
|
||||
Total assets measured at fair value
|
|
$
|
—
|
|
|
$
|
12.4
|
|
|
$
|
47.4
|
|
|
$
|
59.8
|
|
(In millions)
|
Available-for-sale Securities
|
||
Balance at September 29, 2017
|
$
|
47.4
|
|
Reclassification of Original CPTC Loans to Term Loan
|
(47.4
|
)
|
|
Balance at December 29, 2017
|
$
|
—
|
|
(In millions)
|
December 29,
2017 |
|
September 29,
2017 |
||||
Trade and unbilled receivables, gross
|
$
|
955.5
|
|
|
$
|
1,039.2
|
|
Allowance for doubtful accounts
|
(42.6
|
)
|
|
(63.1
|
)
|
||
Trade and unbilled receivables, net
|
$
|
912.9
|
|
|
$
|
976.1
|
|
Short-term
|
$
|
880.1
|
|
|
$
|
961.5
|
|
Long-term
(1)
|
$
|
32.8
|
|
|
$
|
14.6
|
|
|
|
|
|
||||
Notes receivable
|
$
|
86.0
|
|
|
$
|
91.7
|
|
Short-term
(2)
|
$
|
30.0
|
|
|
$
|
5.0
|
|
Long-term
(1)
|
$
|
56.0
|
|
|
$
|
86.7
|
|
(1)
|
Included in other assets on the Company's Condensed Consolidated Balance Sheets.
|
(2)
|
Included in prepaid expenses and other current assets on the Company's Condensed Consolidated Balance Sheets.
|
(In millions)
|
Oncology
Systems
|
|
Varian Particle Therapy
|
|
Total
|
||||||
Balance at September 29, 2017
|
$
|
170.2
|
|
|
$
|
52.4
|
|
|
$
|
222.6
|
|
Foreign currency translation adjustments
|
—
|
|
|
0.8
|
|
|
0.8
|
|
|||
Balance at December 29, 2017
|
$
|
170.2
|
|
|
$
|
53.2
|
|
|
$
|
223.4
|
|
|
December 29, 2017
|
|
September 29, 2017
|
||||||||||||||||||||
(In millions)
|
Gross Carrying Amount
|
|
Accumulated Amortization
|
|
Net Carrying Amount
|
|
Gross Carrying Amount
|
|
Accumulated Amortization
|
|
Net Carrying Amount
|
||||||||||||
Technologies and patents
|
$
|
102.0
|
|
|
$
|
(65.3
|
)
|
|
$
|
36.7
|
|
|
$
|
102.0
|
|
|
$
|
(60.9
|
)
|
|
$
|
41.1
|
|
Customer contracts and supplier relationship
|
33.9
|
|
|
(15.3
|
)
|
|
18.6
|
|
|
33.9
|
|
|
(14.3
|
)
|
|
19.6
|
|
||||||
Other
|
5.5
|
|
|
(4.0
|
)
|
|
1.5
|
|
|
5.5
|
|
|
(3.4
|
)
|
|
2.1
|
|
||||||
Total intangible with finite lives
|
141.4
|
|
|
(84.6
|
)
|
|
56.8
|
|
|
141.4
|
|
|
(78.6
|
)
|
|
62.8
|
|
||||||
In-process research and development with indefinite lives
|
8.8
|
|
|
—
|
|
|
8.8
|
|
|
8.8
|
|
|
—
|
|
|
8.8
|
|
||||||
Total intangible assets
|
$
|
150.2
|
|
|
$
|
(84.6
|
)
|
|
$
|
65.6
|
|
|
$
|
150.2
|
|
|
$
|
(78.6
|
)
|
|
$
|
71.6
|
|
Fiscal Years:
|
Remaining Amortization Expense
|
||
Remainder of 2018
|
$
|
12.6
|
|
2019
|
11.7
|
|
|
2020
|
9.3
|
|
|
2021
|
7.2
|
|
|
2022
|
6.0
|
|
|
Thereafter
|
10.0
|
|
|
Total remaining amortization for intangible assets
|
$
|
56.8
|
|
|
December 29, 2017
|
|
September 29, 2017
|
||||||||||
(In millions, except for percentages)
|
Amount
|
|
Weighted-Average Interest Rate
|
|
Amount
|
|
Weighted-Average Interest Rate
|
||||||
Short-term borrowings:
|
|
|
|
|
|
|
|
||||||
2017 Revolving Credit Facility
|
$
|
340.0
|
|
|
2.49
|
%
|
|
$
|
350.0
|
|
|
2.36
|
%
|
Total short-term borrowings
|
$
|
340.0
|
|
|
|
|
$
|
350.0
|
|
|
|
|
Liability Derivatives
|
||||
|
Balance Sheet
|
|
December 29, 2017
|
||
(In millions)
|
Location
|
|
Fair Value
|
||
Derivatives designated as hedging instruments:
|
|
|
|
||
Foreign exchange forward contracts
|
Accrued liabilities
|
|
$
|
(0.4
|
)
|
Total derivatives
|
|
|
$
|
(0.4
|
)
|
|
December 29, 2017
|
||
(In millions)
|
Notional
Value Sold
|
||
Euro
|
$
|
24.9
|
|
Total
|
$
|
24.9
|
|
|
Location and Amount Recognized in Earnings (Loss) on Cash Flow Hedging Relationships
|
||||||
|
December 29,
|
|
December 30,
|
||||
|
2017
|
|
2016
|
||||
(In millions)
|
Revenues
|
|
Revenues
|
||||
Total amounts of income and expense line items presented in the Condensed Consolidated Statements of Earnings (Loss) in which the effects of fair value and cash flow hedges are recorded
|
$
|
678.5
|
|
|
$
|
601.5
|
|
|
|
|
|
||||
Loss on cash flow hedge relationships:
|
|
|
|
||||
Foreign exchange contracts:
|
|
|
|
||||
Amount of gain reclassified from accumulated other comprehensive loss into earnings (loss)
|
$
|
0.1
|
|
|
$
|
—
|
|
|
December 29, 2017
|
||||||
(In millions)
|
Notional
Value Sold |
|
Notional
Value Purchased |
||||
Australian Dollar
|
$
|
34.7
|
|
|
$
|
—
|
|
Brazilian Real
|
10.9
|
|
|
—
|
|
||
British Pound
|
31.7
|
|
|
—
|
|
||
Canadian Dollar
|
3.4
|
|
|
—
|
|
||
Euro
|
252.1
|
|
|
6.0
|
|
||
Hungarian Forint
|
3.2
|
|
|
—
|
|
||
Indian Rupee
|
11.2
|
|
|
—
|
|
||
Japanese Yen
|
62.9
|
|
|
—
|
|
||
Norwegian Krone
|
2.2
|
|
|
—
|
|
||
Polish Zloty
|
33.2
|
|
|
—
|
|
||
Swiss Franc
|
—
|
|
|
40.9
|
|
||
Thai Baht
|
4.6
|
|
|
—
|
|
||
Totals
|
$
|
450.1
|
|
|
$
|
46.9
|
|
Location of Gain (Loss) Recognized in Income on Derivative Instruments
|
|
Amount of Gain (Loss) Recognized in Net Earnings (Loss) on Derivative Instruments
|
||||||
|
|
Three Months Ended
|
||||||
(In millions)
|
|
December 29,
2017 |
|
December 30,
2016 |
||||
Selling, general and administrative expenses
|
|
$
|
(4.7
|
)
|
|
$
|
14.9
|
|
|
Three Months Ended
|
||||||
(In millions)
|
December 29,
2017 |
|
December 30,
2016 |
||||
Accrued product warranty, at beginning of period
|
$
|
41.3
|
|
|
$
|
41.9
|
|
Charged to cost of revenues
|
14.4
|
|
|
9.2
|
|
||
Actual product warranty expenditures
|
(8.6
|
)
|
|
(12.1
|
)
|
||
Accrued product warranty, at end of period
|
$
|
47.1
|
|
|
$
|
39.0
|
|
(In millions)
|
September 29,
2017 |
|
Restructuring Charges
|
|
Cash Payments
|
|
December 29,
2017 |
||||||||
2017 Restructuring Plan
|
$
|
3.9
|
|
|
$
|
—
|
|
|
$
|
(2.2
|
)
|
|
$
|
1.7
|
|
Total
|
$
|
3.9
|
|
|
$
|
—
|
|
|
$
|
(2.2
|
)
|
|
$
|
1.7
|
|
|
Three Months Ended
|
||||||
(In millions)
|
December 29,
2017 |
|
December 30,
2016 |
||||
Defined Benefit Plans
|
|
|
|
||||
Service cost
|
$
|
1.6
|
|
|
$
|
1.7
|
|
Interest cost
|
0.8
|
|
|
0.6
|
|
||
Expected return on plan assets
|
(2.0
|
)
|
|
(1.7
|
)
|
||
Amortization of prior service cost
|
(0.1
|
)
|
|
(0.1
|
)
|
||
Recognized actuarial loss
|
0.7
|
|
|
1.1
|
|
||
Net periodic benefit cost
|
$
|
1.0
|
|
|
$
|
1.6
|
|
|
Three Months Ended
|
||||||
(In millions, except per share amounts)
|
December 29,
2017 |
|
December 30,
2016 |
||||
Number of shares
|
0.5
|
|
|
0.5
|
|
||
Average repurchase price per share
|
$
|
108.16
|
|
|
$
|
98.98
|
|
Total cost
|
$
|
56.7
|
|
|
$
|
49.5
|
|
(In millions)
|
Net Unrealized Gains
(Losses) Defined Benefit Pension and Post-Retirement Benefit Plans |
|
Net
Unrealized Gains (Losses) Cash Flow Hedging Instruments |
|
Cumulative
Translation Adjustment |
|
Accumulated
Other Comprehensive Loss |
||||||||
Balance at September 29, 2017
|
$
|
(44.1
|
)
|
|
$
|
—
|
|
|
$
|
(24.7
|
)
|
|
$
|
(68.8
|
)
|
Other comprehensive earnings (loss) before reclassifications
|
—
|
|
|
(0.3
|
)
|
|
3.1
|
|
|
2.8
|
|
||||
Amounts reclassified out of other comprehensive earnings (loss)
|
0.4
|
|
|
(0.1
|
)
|
|
—
|
|
|
0.3
|
|
||||
Tax (expense) benefit
|
(0.1
|
)
|
|
0.1
|
|
|
—
|
|
|
—
|
|
||||
Balance at December 29, 2017
|
$
|
(43.8
|
)
|
|
$
|
(0.3
|
)
|
|
$
|
(21.6
|
)
|
|
$
|
(65.7
|
)
|
(In millions)
|
Net Unrealized Gains
(Losses) Defined Benefit Pension and Post-Retirement Benefit Plans |
|
Cumulative
Translation Adjustment |
|
Accumulated
Other Comprehensive Earnings (Loss) |
||||||
Balance at September 30, 2016
|
$
|
(63.3
|
)
|
|
$
|
(37.5
|
)
|
|
$
|
(100.8
|
)
|
Other comprehensive loss before reclassifications
|
—
|
|
|
(13.1
|
)
|
|
(13.1
|
)
|
|||
Amounts reclassified out of other comprehensive earnings
|
0.9
|
|
|
—
|
|
|
0.9
|
|
|||
Tax expense
|
(0.1
|
)
|
|
—
|
|
|
(0.1
|
)
|
|||
Balance at December 30, 2016
|
$
|
(62.5
|
)
|
|
$
|
(50.6
|
)
|
|
$
|
(113.1
|
)
|
|
Three Months Ended
|
|
||||||
(In millions)
|
December 29,
2017 |
|
December 30,
2016 |
|
||||
Comprehensive Earnings Components
|
Income (Loss) Before Taxes
|
Line Item in Statements of Earnings (Loss)
|
||||||
Unrealized loss on defined benefit pension and post-retirement benefit plans
|
$
|
(0.4
|
)
|
|
$
|
(0.9
|
)
|
Cost of revenues & Operating expenses
|
Unrealized gain on cash flow hedging instruments
|
0.1
|
|
|
—
|
|
Revenues
|
||
Total amounts reclassified out of other comprehensive earnings
|
$
|
(0.3
|
)
|
|
$
|
(0.9
|
)
|
|
|
Three Months Ended
|
||||||||||
|
December 29, 2017
|
|
December 30, 2016
|
||||||||
(In millions)
|
Noncontrolling Interests
|
|
Noncontrolling Interests
|
|
Redeemable Noncontrolling Interests
|
||||||
Beginning of Period
|
$
|
4.3
|
|
|
$
|
3.7
|
|
|
$
|
10.3
|
|
Net earnings attributable to noncontrolling interests
|
0.1
|
|
|
0.5
|
|
|
0.1
|
|
|||
Other
|
—
|
|
|
—
|
|
|
(0.1
|
)
|
|||
End of Period
|
$
|
4.4
|
|
|
$
|
4.2
|
|
|
$
|
10.3
|
|
|
Three Months Ended
|
||||||
(In millions)
|
December 29,
2017 |
|
December 30,
2016 |
||||
Cost of revenues - Product
|
$
|
0.7
|
|
|
$
|
0.8
|
|
Cost of revenues - Service
|
1.0
|
|
|
1.0
|
|
||
Research and development
|
1.2
|
|
|
1.2
|
|
||
Selling, general and administrative
|
7.8
|
|
|
7.2
|
|
||
Total share-based compensation expense
|
$
|
10.7
|
|
|
$
|
10.2
|
|
Income tax benefit for share-based compensation
|
$
|
(2.1
|
)
|
|
$
|
(3.0
|
)
|
|
Three Months Ended
|
||||||
|
December 29,
2017 |
|
December 30,
2016 |
||||
Employee Stock Option Plans
|
|
|
|
||||
Expected term (in years)
|
3.82
|
|
|
4.13
|
|
||
Risk-free interest rate
|
1.9
|
%
|
|
1.4
|
%
|
||
Expected volatility
|
18.7
|
%
|
|
20.5
|
%
|
||
Expected dividend
|
—
|
%
|
|
—
|
%
|
||
Weighted average fair value at grant date
|
$
|
19.45
|
|
|
$
|
15.44
|
|
|
Three Months Ended
|
||||||
|
December 29,
2017 |
|
December 30,
2016 |
||||
Employee Stock Purchase Plan
|
|
|
|
||||
Expected term (in years)
|
0.50
|
|
|
0.50
|
|
||
Risk-free interest rate
|
1.2
|
%
|
|
0.5
|
%
|
||
Expected volatility
|
17.9
|
%
|
|
22.3
|
%
|
||
Expected dividend
|
—
|
%
|
|
—
|
%
|
||
Weighted average fair value at grant date
|
$
|
20.97
|
|
|
$
|
19.37
|
|
(In millions)
|
Shares Available for Grant
|
|
Balance at September 29, 2017
|
2.5
|
|
Granted
|
(0.8
|
)
|
Cancelled or expired
|
0.3
|
|
Balance at December 29, 2017
|
2.0
|
|
|
Options Outstanding
|
|||||||||||
(In millions, except per share amounts)
|
Number of
Shares |
|
Weighted
Average Exercise Price |
|
Weighted
Average Remaining Term (in years) |
|
Aggregate
Intrinsic Value (1) |
|||||
Balance at September 29, 2017
|
2.3
|
|
|
$
|
74.08
|
|
|
|
|
|
||
Granted
|
0.2
|
|
|
109.05
|
|
|
|
|
|
|||
Cancelled or expired
(2)
|
—
|
|
|
75.38
|
|
|
|
|
|
|||
Exercised
|
(0.2
|
)
|
|
67.62
|
|
|
|
|
|
|||
Balance at December 29, 2017
|
2.3
|
|
|
$
|
78.45
|
|
|
4.8
|
|
$
|
74.3
|
|
|
|
|
|
|
|
|
|
|||||
Exercisable at December 29, 2017
|
1.1
|
|
|
$
|
72.45
|
|
|
3.7
|
|
$
|
41.2
|
|
(1)
|
The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of VMS common stock of
$111.15
as of
December 29, 2017
, the last trading date of the
first
quarter of fiscal year
2018
, and which represents the amount that would have been received by the option holders had all option holders exercised their options and sold the shares received upon exercise as of that date.
|
(2)
|
The cancelled and expired shares were not material for disclosure.
|
(In millions, except per share amounts)
|
Number of
Shares |
|
Weighted Average
Grant-Date Fair Value |
|||
Balance at September 29, 2017
|
0.9
|
|
|
$
|
75.37
|
|
Granted
|
0.1
|
|
|
109.16
|
|
|
Vested
(1)
|
—
|
|
|
74.62
|
|
|
Cancelled or expired
|
(0.1
|
)
|
|
84.96
|
|
|
Balance at December 29, 2017
|
0.9
|
|
|
$
|
79.38
|
|
(1)
|
The vested shares were not material for disclosure.
|
|
Three Months Ended
|
||||||
(In millions, except per share amounts)
|
December 29,
2017 |
|
December 30,
2016 |
||||
Net earnings (loss) from continuing operations
|
$
|
(112.2
|
)
|
|
$
|
8.0
|
|
Less: Net earnings from continuing operations attributable to noncontrolling interests
|
0.1
|
|
|
0.5
|
|
||
Net earnings (loss) from continuing operations attributable to Varian
|
$
|
(112.3
|
)
|
|
$
|
7.5
|
|
|
|
|
|
||||
Net earnings from discontinued operations
|
$
|
—
|
|
|
$
|
6.5
|
|
Less: Net earnings from discontinued operations attributable to noncontrolling interests
|
—
|
|
|
0.1
|
|
||
Net earnings from discontinued operations attributable to Varian
|
—
|
|
|
6.4
|
|
||
Net earnings (loss) attributable to Varian
|
$
|
(112.3
|
)
|
|
$
|
13.9
|
|
|
|
|
|
||||
Weighted average shares outstanding - basic
|
91.6
|
|
|
93.5
|
|
||
Dilutive effect of potential common shares
|
—
|
|
|
0.7
|
|
||
Weighted average shares outstanding - diluted
|
91.6
|
|
|
94.2
|
|
||
|
|
|
|
||||
Net earnings (loss) per share attributable to Varian - basic
|
|
|
|
||||
Continuing operations
|
$
|
(1.22
|
)
|
|
$
|
0.08
|
|
Discontinued operations
|
—
|
|
|
0.07
|
|
||
Net earnings per share - basic
|
$
|
(1.22
|
)
|
|
$
|
0.15
|
|
|
|
|
|
||||
Net earnings (loss) per share attributable to Varian - diluted
|
|
|
|
||||
Continuing operations
|
$
|
(1.22
|
)
|
|
$
|
0.08
|
|
Discontinued operations
|
—
|
|
|
0.07
|
|
||
Net earnings per share - diluted
|
$
|
(1.22
|
)
|
|
$
|
0.15
|
|
Anti-dilutive employee share-based awards, excluded
|
3.2
|
|
|
0.6
|
|
|
|
December 29, 2017
|
|
September 29, 2017
|
||||||||||||
(In millions)
|
|
Balance
|
|
Commitment
|
|
Balance
|
|
Commitment
|
||||||||
Notes receivable and secured debt:
|
|
|
|
|
|
|
|
|
||||||||
MPTC loans
(1)
|
|
$
|
60.1
|
|
|
$
|
—
|
|
|
$
|
60.1
|
|
|
$
|
—
|
|
RPTC senior secured debt
(2)
|
|
25.8
|
|
|
—
|
|
|
25.4
|
|
|
—
|
|
||||
NYPC loan
(3)
|
|
18.5
|
|
|
—
|
|
|
18.5
|
|
|
—
|
|
||||
PI loan
(3)
|
|
2.5
|
|
|
—
|
|
|
3.0
|
|
|
—
|
|
||||
CPTC DIP loan
(3)
|
|
—
|
|
|
—
|
|
|
5.1
|
|
|
2.2
|
|
||||
|
|
$
|
106.9
|
|
|
$
|
—
|
|
|
$
|
112.1
|
|
|
$
|
2.2
|
|
Available-for-sale Securities:
|
|
|
|
|
|
|
|
|
||||||||
Original CPTC loans
(3)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
47.4
|
|
|
$
|
—
|
|
DRTC securities
(4)
|
|
8.0
|
|
|
—
|
|
|
8.0
|
|
|
—
|
|
||||
APTC securities
(2)
|
|
6.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
GPTC securities
(3)
|
|
4.5
|
|
|
11.8
|
|
|
4.4
|
|
|
11.8
|
|
||||
|
|
$
|
18.5
|
|
|
$
|
11.8
|
|
|
$
|
59.8
|
|
|
$
|
11.8
|
|
|
|
|
|
|
|
|
|
|
||||||||
CPTC Loans and Investment:
|
|
|
|
|
|
|
|
|
||||||||
Short-term revolving loan
(2)
|
|
$
|
2.4
|
|
|
$
|
4.8
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Term loan
(3)
|
|
44.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Equity investment in CPTC
(3)
|
|
9.5
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
|
|
$
|
55.9
|
|
|
$
|
4.8
|
|
|
$
|
—
|
|
|
$
|
—
|
|
(1)
|
Includes
$35.0 million
in other assets at both
December 29, 2017
and
September 29, 2017
, respectively, and
$25.1 million
in prepaid and other current assets at
December 29, 2017
and other assets at
September 29, 2017
on the Company's Condensed Consolidated Balance Sheets.
|
(2)
|
Included in prepaid and other current assets on the Company's Condensed Consolidated Balance Sheets.
|
(3)
|
Included in other assets on the Company's Condensed Consolidated Balance Sheets.
|
(4)
|
Included in prepaid and other current assets at
December 29, 2017
and in other assets at
September 29, 2017
on the Company's Condensed Consolidated Balance Sheets.
|
|
Three Months Ended
|
||||||
(In millions)
|
December 29,
2017 |
|
December 30,
2016 |
||||
Revenues
|
|
|
|
||||
Oncology Systems
|
$
|
649.4
|
|
|
$
|
571.2
|
|
Varian Particle Therapy
|
29.1
|
|
|
30.3
|
|
||
Total Company
|
$
|
678.5
|
|
|
$
|
601.5
|
|
Operating Earnings
|
|
|
|
||||
Oncology Systems
|
$
|
138.2
|
|
|
$
|
116.1
|
|
Varian Particle Therapy
|
(15.2
|
)
|
|
(50.3
|
)
|
||
Total reportable segments
|
123.0
|
|
|
65.8
|
|
||
Unallocated corporate
|
(1.6
|
)
|
|
(48.4
|
)
|
||
Total Company
|
$
|
121.4
|
|
|
$
|
17.4
|
|
Total Revenues by product type
|
Three Months Ended December 29, 2017
|
||||||||||
(In millions)
|
Oncology
|
|
VPT
|
|
Total
|
||||||
Hardware
|
$
|
293.1
|
|
|
$
|
27.3
|
|
|
$
|
320.4
|
|
Software
(1)
|
115.1
|
|
|
—
|
|
|
115.1
|
|
|||
Service
|
241.2
|
|
|
1.8
|
|
|
243.0
|
|
|||
Total Revenues
|
$
|
649.4
|
|
|
$
|
29.1
|
|
|
$
|
678.5
|
|
(1)
|
Includes software support agreements that are recorded in revenues from service in the Condensed Consolidated Statements of Earnings (Loss).
|
Total Revenues by product type
|
Three Months Ended December 30, 2016
|
||||||||||
(In millions)
|
Oncology
|
|
VPT
|
|
Total
|
||||||
Hardware
|
$
|
238.6
|
|
|
$
|
26.8
|
|
|
$
|
265.4
|
|
Software
(1)
|
112.2
|
|
|
—
|
|
|
112.2
|
|
|||
Service
|
220.4
|
|
|
3.5
|
|
|
223.9
|
|
|||
Total Revenues
|
$
|
571.2
|
|
|
$
|
30.3
|
|
|
$
|
601.5
|
|
(1)
|
Includes software support agreements that are recorded in revenues from service in the Condensed Consolidated Statements of Earnings (Loss).
|
Total Revenues by geographical region
|
Three Months Ended December 29, 2017
|
||||||||||
(In millions)
|
Oncology
|
|
VPT
|
|
Total
|
||||||
Americas
|
$
|
337.4
|
|
|
$
|
19.3
|
|
|
$
|
356.7
|
|
EMEA
|
183.5
|
|
|
9.5
|
|
|
193.0
|
|
|||
APAC
|
128.5
|
|
|
0.3
|
|
|
128.8
|
|
|||
Total Revenues
|
$
|
649.4
|
|
|
$
|
29.1
|
|
|
$
|
678.5
|
|
|
|
|
|
|
|
||||||
North America
|
$
|
326.3
|
|
|
$
|
19.3
|
|
|
$
|
345.6
|
|
International
|
323.1
|
|
|
9.8
|
|
|
332.9
|
|
|||
Total Revenues
|
$
|
649.4
|
|
|
$
|
29.1
|
|
|
$
|
678.5
|
|
Total Revenues by geographical region
|
Three Months Ended December 30, 2016
|
||||||||||
(In millions)
|
Oncology
|
|
VPT
|
|
Total
|
||||||
Americas
|
$
|
290.8
|
|
|
$
|
7.4
|
|
|
$
|
298.2
|
|
EMEA
|
169.0
|
|
|
15.0
|
|
|
184.0
|
|
|||
APAC
|
111.4
|
|
|
7.9
|
|
|
119.3
|
|
|||
Total Revenues
|
$
|
571.2
|
|
|
$
|
30.3
|
|
|
$
|
601.5
|
|
|
|
|
|
|
|
||||||
North America
|
$
|
275.0
|
|
|
$
|
7.4
|
|
|
$
|
282.4
|
|
International
|
296.2
|
|
|
22.9
|
|
|
319.1
|
|
|||
Total Revenues
|
$
|
571.2
|
|
|
$
|
30.3
|
|
|
$
|
601.5
|
|
Timing of revenue recognition
|
Three Months Ended December 29, 2017
|
||||||||||
(In millions)
|
Products transferred at a point in time
|
|
Products and Services transferred over time
|
|
Total
|
||||||
Oncology Systems
|
$
|
338.3
|
|
|
$
|
311.1
|
|
|
$
|
649.4
|
|
VPT
|
—
|
|
|
29.1
|
|
|
29.1
|
|
|||
Total Revenues
|
$
|
338.3
|
|
|
$
|
340.2
|
|
|
$
|
678.5
|
|
Timing of revenue recognition
|
Three Months Ended December 30, 2016
|
||||||||||
(In millions)
|
Products Transferred at a Point in Time
|
|
Products and Services Transferred Over Time
|
|
Total
|
||||||
Oncology Systems
|
$
|
282.4
|
|
|
$
|
288.8
|
|
|
$
|
571.2
|
|
VPT
|
—
|
|
|
30.3
|
|
|
30.3
|
|
|||
Total Revenues
|
$
|
282.4
|
|
|
$
|
319.1
|
|
|
$
|
601.5
|
|
Revenues by sales classification
|
Three Months Ended
|
|||||||||
(Dollars in millions)
|
December 29,
2017 |
|
December 30,
2016 |
|
Percent Change
|
|||||
Product
|
$
|
365.6
|
|
|
$
|
309.2
|
|
|
18
|
%
|
Service
|
312.9
|
|
|
292.3
|
|
|
7
|
%
|
||
Total Revenues
|
$
|
678.5
|
|
|
$
|
601.5
|
|
|
13
|
%
|
Product as a percentage of total revenues
|
54
|
%
|
|
51
|
%
|
|
|
|||
Service as a percentage of total revenues
|
46
|
%
|
|
49
|
%
|
|
|
Revenues by geographical region
|
Three Months Ended
|
||||||||||||
(Dollars in millions)
|
December 29,
2017 |
|
December 30,
2016 |
|
Percent Change
|
|
Constant Currency
(1)
|
||||||
Americas
|
$
|
356.7
|
|
|
$
|
298.2
|
|
|
20
|
%
|
|
20
|
%
|
EMEA
|
193.0
|
|
|
184.0
|
|
|
5
|
%
|
|
(2
|
)%
|
||
APAC
|
128.8
|
|
|
119.3
|
|
|
8
|
%
|
|
10
|
%
|
||
Total Revenues
|
$
|
678.5
|
|
|
$
|
601.5
|
|
|
13
|
%
|
|
11
|
%
|
|
|
|
|
|
|
|
|
||||||
North America
|
$
|
345.6
|
|
|
$
|
282.4
|
|
|
22
|
%
|
|
22
|
%
|
International
(2)
|
332.9
|
|
|
319.1
|
|
|
4
|
%
|
|
1
|
%
|
||
Total Revenues
|
$
|
678.5
|
|
|
$
|
601.5
|
|
|
13
|
%
|
|
11
|
%
|
North America as a percentage of total revenues
|
51
|
%
|
|
46
|
%
|
|
|
|
|
||||
International as a percentage of total revenues
|
49
|
%
|
|
54
|
%
|
|
|
|
|
(1)
|
Constant currency is the percent change excluding the effect of foreign currency fluctuations against the U.S. Dollar.
|
(2)
|
We consider international revenues to be revenues outside of North America.
|
Revenues by sales classification
|
Three Months Ended
|
||||||||||||
(Dollars in millions)
|
December 29,
2017 |
|
December 30,
2016 |
|
Percent Change
|
|
Constant Currency
|
||||||
Product
|
$
|
338.3
|
|
|
$
|
282.4
|
|
|
20
|
%
|
|
18
|
%
|
Service
|
311.1
|
|
|
288.8
|
|
|
8
|
%
|
|
6
|
%
|
||
Total Oncology Systems Revenues
|
$
|
649.4
|
|
|
$
|
571.2
|
|
|
14
|
%
|
|
12
|
%
|
Product as a percentage of total Oncology Systems revenues
|
52
|
%
|
|
49
|
%
|
|
|
|
|
||||
Service as a percentage of total Oncology Systems revenues
|
48
|
%
|
|
51
|
%
|
|
|
|
|
||||
Oncology Systems revenues as a percentage of total revenues
|
96
|
%
|
|
95
|
%
|
|
|
|
|
Revenues by geographical region
|
Three Months Ended
|
||||||||||||
(Dollars in millions)
|
December 29,
2017 |
|
December 30,
2016 |
|
Percent Change
|
|
Constant Currency
|
||||||
Americas
|
$
|
337.4
|
|
|
$
|
290.8
|
|
|
16
|
%
|
|
16
|
%
|
EMEA
|
183.5
|
|
|
169.0
|
|
|
9
|
%
|
|
2
|
%
|
||
APAC
|
128.5
|
|
|
111.4
|
|
|
15
|
%
|
|
17
|
%
|
||
Total Oncology Systems Revenues
|
$
|
649.4
|
|
|
$
|
571.2
|
|
|
14
|
%
|
|
12
|
%
|
|
|
|
|
|
|
|
|
||||||
North America
|
$
|
326.3
|
|
|
$
|
275.0
|
|
|
19
|
%
|
|
19
|
%
|
International
|
323.1
|
|
|
296.2
|
|
|
9
|
%
|
|
6
|
%
|
||
Total Oncology Systems Revenues
|
$
|
649.4
|
|
|
$
|
571.2
|
|
|
14
|
%
|
|
12
|
%
|
North America as a percentage of total Oncology Systems revenues
|
50
|
%
|
|
47
|
%
|
|
|
|
|
||||
International as a percentage of total Oncology Systems revenues
|
50
|
%
|
|
53
|
%
|
|
|
|
|
Revenues by sales classification
|
Three Months Ended
|
|||||||||
(Dollars in millions)
|
December 29,
2017 |
|
December 30,
2016 |
|
Percent Change
|
|||||
Product
|
$
|
27.3
|
|
|
$
|
26.8
|
|
|
2
|
%
|
Service
|
1.8
|
|
|
3.5
|
|
|
(49
|
)%
|
||
Total Varian Particle Therapy Revenues
|
$
|
29.1
|
|
|
$
|
30.3
|
|
|
(4
|
)%
|
VPT revenues as a percentage of total revenues
|
4
|
%
|
|
5
|
%
|
|
|
Dollars by segment
|
Three Months Ended
|
|||||||||
(Dollars in millions)
|
December 29,
2017 |
|
December 30,
2016 |
|
Percent Change
|
|||||
Oncology Systems
|
$
|
300.5
|
|
|
$
|
262.1
|
|
|
15
|
%
|
Varian Particle Therapy
|
2.3
|
|
|
4.9
|
|
|
(52
|
)%
|
||
Gross margin
|
$
|
302.8
|
|
|
$
|
267.0
|
|
|
13
|
%
|
|
|
|
|
|
|
|||||
Percentage by segment
|
|
|
|
|
|
|||||
Oncology Systems
|
46.3
|
%
|
|
45.9
|
%
|
|
|
|||
Varian Particle Therapy
|
8.0
|
%
|
|
16.1
|
%
|
|
|
|||
Total Company
|
44.6
|
%
|
|
44.4
|
%
|
|
|
|||
|
|
|
|
|
|
|||||
Percentage by sales classification
|
|
|
|
|
|
|||||
Total Company - Product
|
38.8
|
%
|
|
33.3
|
%
|
|
|
|||
Total Company - Service
|
51.5
|
%
|
|
56.1
|
%
|
|
|
|
Three Months Ended
|
|||||||||
(Dollars in millions)
|
December 29,
2017 |
|
December 30,
2016 |
|
Percent Change
|
|||||
Research and development
|
$
|
55.9
|
|
|
$
|
49.9
|
|
|
12
|
%
|
Research and development as a percentage of total revenues
|
8
|
%
|
|
8
|
%
|
|
|
|
Three Months Ended
|
|||||||||
(Dollars in millions)
|
December 29,
2017 |
|
December 30,
2016 |
|
Percent Change
|
|||||
Selling, general and administrative
|
$
|
125.5
|
|
|
$
|
161.4
|
|
|
(22
|
)%
|
Impairment charges
|
—
|
|
|
38.3
|
|
|
n/m
|
|
||
Selling, general and administrative as a percentage of total revenues
|
18
|
%
|
|
27
|
%
|
|
|
|||
Impairment charges as a percentage of total revenues
|
—
|
%
|
|
6
|
%
|
|
|
|
Three Months Ended
|
|||||||||
(Dollars in millions)
|
December 29,
2017 |
|
December 30,
2016 |
|
Percent Change
|
|||||
Interest income, net
|
$
|
1.1
|
|
|
$
|
1.9
|
|
|
(43
|
)%
|
|
Three Months Ended
|
|||||||
|
December 29,
2017 |
|
December 30,
2016 |
|
Percent Change
|
|||
Effective tax rate
|
191.5
|
%
|
|
58.6
|
%
|
|
132.9
|
%
|
|
Three Months Ended
(1)
|
||
(In millions)
|
December 30,
2016 |
||
Revenues
|
$
|
151.5
|
|
Cost of revenues
|
92.7
|
|
|
Gross margin
|
58.8
|
|
|
Operating expenses
(2)
|
46.4
|
|
|
Operating earnings
|
12.4
|
|
|
Taxes on earnings
|
5.9
|
|
|
Net earnings from discontinued operations
|
$
|
6.5
|
|
(1)
|
There was no activity in net earnings from discontinued operations during the first quarter of fiscal year
2018
.
|
(2)
|
Operating expenses from discontinued operations included separation costs of
$14.9 million
during the first quarter of fiscal year
2017
. Separation costs include expenses for transaction advisory services, consulting services, restructuring and other expenses.
|
|
Three Months Ended
|
||||||||
|
December 29,
2017 |
|
December 30,
2016 |
|
Percent Change
|
||||
Diluted net earnings (loss) per share - continuing operations
|
$
|
(1.22
|
)
|
|
$
|
0.08
|
|
|
n/m
|
Diluted net earnings per share - discontinued operations
|
—
|
|
|
0.07
|
|
|
n/m
|
||
Total - Diluted net earnings (loss) per share
|
$
|
(1.22
|
)
|
|
$
|
0.15
|
|
|
n/m
|
Total Gross Orders by segment
|
Three Months Ended
|
|||||||||
(Dollars in millions)
|
December 29,
2017 |
|
December 30,
2016 |
|
Percent Change
|
|||||
Oncology Systems
|
$
|
619.9
|
|
|
$
|
576.7
|
|
|
7
|
%
|
Varian Particle Therapy
|
46.2
|
|
|
4.3
|
|
|
965
|
%
|
||
Total Gross Orders
|
$
|
666.1
|
|
|
$
|
581.0
|
|
|
15
|
%
|
Gross Orders by geographical region
|
Three Months Ended
|
||||||||||||
(Dollars in millions)
|
December 29,
2017 |
|
December 30,
2016 |
|
Percent Change
|
|
Constant Currency
|
||||||
Americas
|
$
|
299.5
|
|
|
$
|
293.6
|
|
|
2
|
%
|
|
2
|
%
|
EMEA
|
190.4
|
|
|
160.1
|
|
|
19
|
%
|
|
13
|
%
|
||
APAC
|
130.0
|
|
|
123.0
|
|
|
6
|
%
|
|
6
|
%
|
||
Total Oncology Systems Gross Orders
|
$
|
619.9
|
|
|
$
|
576.7
|
|
|
7
|
%
|
|
6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|||
North America
|
$
|
278.7
|
|
|
$
|
272.2
|
|
|
2
|
%
|
|
2
|
%
|
International
|
341.2
|
|
|
304.5
|
|
|
12
|
%
|
|
9
|
%
|
||
Total Oncology Systems Gross Orders
|
$
|
619.9
|
|
|
$
|
576.7
|
|
|
7
|
%
|
|
6
|
%
|
|
Trailing 12 Months Ended
|
||||||
|
December 29, 2017
|
|
September 29, 2017
|
|
June 30, 2017
|
|
March 31, 2017
|
Americas
|
1%
|
|
1%
|
|
4%
|
|
5%
|
EMEA
|
14%
|
|
12%
|
|
1%
|
|
—%
|
APAC
|
3%
|
|
7%
|
|
14%
|
|
15%
|
North America
|
3%
|
|
4%
|
|
2%
|
|
5%
|
International
|
7%
|
|
7%
|
|
7%
|
|
6%
|
Total Oncology Systems Gross Orders
|
5%
|
|
5%
|
|
5%
|
|
5%
|
(In millions)
|
December 29,
2017 |
|
September 29,
2017 |
|
Increase
|
||||||
Total cash and cash equivalents
|
$
|
822.6
|
|
|
$
|
716.2
|
|
|
$
|
106.4
|
|
|
Three Months Ended
|
||||||
(In millions)
|
December 29,
2017 |
|
December 30,
2016 |
||||
Net cash flow provided by (used in):
|
|
|
|
||||
Operating activities
|
$
|
179.0
|
|
|
$
|
82.2
|
|
Investing activities
|
(25.8
|
)
|
|
(31.8
|
)
|
||
Financing activities
|
(42.8
|
)
|
|
(89.6
|
)
|
||
Effects of exchange rate changes on cash and cash equivalents
|
(4.0
|
)
|
|
10.4
|
|
||
Net increase (decrease) in cash and cash equivalents
|
$
|
106.4
|
|
|
$
|
(28.8
|
)
|
•
|
In the
first quarter
of fiscal year
2018
, we generated net cash from operating activities of
$179.0 million
compared to
$82.2 million
in the
first quarter
of fiscal year
2017
. The
$96.8 million
increase
in net cash from operating activities was driven by a
$236.8 million
increase
in the net change from operating assets and liabilities partially offset by a
$126.7 million
decrease
in net earnings and a
$13.3 million
decrease
from non-cash items.
|
•
|
The major contributors to the net change in operating assets and liabilities in the
first quarter
of fiscal year
2018
were as follows:
|
◦
|
Accrued liabilities and other long-term liabilities
increased
$125.1 million
primarily due an increase in a long-term income tax liability that resulted from the tax legislation that was signed into law in the first quarter of fiscal year
2018
.
|
◦
|
Trade and unbilled receivables
decreased
$65.9 million
primarily due to higher collections than billings partially offset by an increase in unbilled receivables.
|
◦
|
Prepaid and other assets
decreased
$28.2 million
primarily due to a decrease in prepaid income taxes.
|
◦
|
Deferred revenues
increased
$18.6 million
primarily due to advance payments received from VPT customers and an increase in deferred service revenues in Oncology Systems.
|
◦
|
Inventory
increased
$11.7 million
primarily due an increase in hardware product inventory in Oncology Systems.
|
•
|
In the
first quarter
of fiscal year
2018
, cash used for investing activities was
$25.8 million
, compared to cash used of
$31.8 million
in the
first quarter
of fiscal year
2017
. In the
first quarter
of fiscal year
2018
, cash used for investing activities primarily included
$9.3 million
in purchases of property, plant and equipment,
$6.0 million
in investment in available-for-sale securities,
$4.6 million
in loans to CPTC, a
$2.6 million
deposit in an escrow account related to a potential acquisition, and a
$2.5 million
investment in a privately-held company. In the
first quarter
of fiscal year
2017
, cash used for investing activities primarily included
$17.2 million
in purchases of property, plant and equipment, a
$11.4 million
issuance of a notes receivable, and
$3.4 million
paid to our deferred compensation plan trust account.
|
•
|
In the
first quarter
of fiscal year
2018
, cash used in financing activities was
$42.8 million
compared to
$89.6 million
used in the
first quarter
of fiscal year
2017
. In the
first quarter
of fiscal year
2018
, cash used for financing activities primarily included
$56.7 million
for the repurchase of VMS common stock,
$10.0 million
in debt repayments, net of borrowings, partially offset by
$24.2 million
received from the issuance of common stock to employees. In the
first quarter
of fiscal year
2017
, cash used for financing activities primarily included
$55.0 million
in borrowings, net of debt repayments, under our credit facility agreements,
$49.5 million
for the repurchase of VMS common stock, partially offset by
$16.1 million
received from the issuance of common stock to employees.
|
|
December 29, 2017
|
|
September 29, 2017
|
||||||||||
(Dollars in millions)
|
Amount
|
|
Weighted-Average Interest Rate
|
|
Amount
|
|
Weighted-Average Interest Rate
|
||||||
Short-term borrowings:
|
|
|
|
|
|
|
|
||||||
2017 Revolving Credit Facility
|
$
|
340.0
|
|
|
2.49
|
%
|
|
$
|
350.0
|
|
|
2.36
|
%
|
(Dollars in millions)
|
First Quarter of Fiscal Year 2018
|
||
Amount outstanding (at end of period)
|
$
|
340.0
|
|
Weighted average interest rate (at end of period)
|
2.49
|
%
|
|
Average amount outstanding (during period)
|
$
|
257.6
|
|
Weighted average interest rate (during period)
|
2.40
|
%
|
|
Maximum month-end amount outstanding during period
|
$
|
340.0
|
|
|
Three Months Ended
|
||||||
(In millions, except per share amounts)
|
December 29,
2017 |
|
December 30,
2016 |
||||
Number of shares
|
0.5
|
|
|
0.5
|
|
||
Average repurchase price per share
|
$
|
108.16
|
|
|
$
|
98.98
|
|
Total cost
|
$
|
56.7
|
|
|
$
|
49.5
|
|
(a)
|
Disclosure controls and procedures.
Based on the evaluation of our disclosure controls and procedures (as defined in the Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) required by Exchange Act Rules 13a-15(b) or 15d-15(b), our principal executive officer and principal financial officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and include controls and procedures designed to ensure that information required to be disclosed by us in such reports is accumulated and communicated to our management, including the principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
|
(b)
|
Changes in internal control over financial reporting.
Beginning September 30, 2017, we implemented ASC 606, Revenue from Contracts with Customers. As a result, we implemented changes to our processes related to revenue recognition, the control activities within them, and the key system functionalities to enable the preparation of financial information. This included the development of new policies based on the five-step model provided in the new revenue standard. There were no other changes in our internal control over financial reporting that occurred during the first quarter of fiscal year 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
|
•
|
our ability to retain key employees of the acquired company;
|
•
|
the performance of the acquired business, technology, product or service;
|
•
|
our ability to integrate operations, financial and other systems;
|
•
|
the ability of the combined company to achieve synergies among its constituent companies, such as increasing sales of the combined company’s products and services, achieving expected cost savings and effectively combining technologies to develop new products and services;
|
•
|
any disruption in order fulfillment or loss of sales due to integration processes;
|
•
|
the presence or absence of adequate internal controls and/or significant fraud in the financial systems of acquired companies;
|
•
|
any decrease in customer and distributor loyalty and product orders caused by dissatisfaction with the acquired companies’ product lines and sales and marketing practices, including price increases; and
|
•
|
our assumption of known contingent liabilities that are realized, known liabilities that prove greater than anticipated, or unknown liabilities that come to light, to the extent that the realization of any of these liabilities increases our expenses or adversely affects our business or financial position.
|
(a)
|
Not applicable
|
(b)
|
Not applicable
|
(c)
|
The following table provides information with respect to the shares of common stock repurchased by us during the
first
quarter of fiscal year
2018
(in millions, except per share amounts):
|
Period
|
Total Number of
Shares Purchased
|
|
Average Price
Paid Per Share
|
|
Total Number of
Shares Purchased as
Part of Publicly
Announced Plans or
Programs
|
|
Maximum Number
of Shares that May
Yet Be Purchased
Under the Plans or
Programs (1) |
|||||
September 30, 2017 - October 27, 2017
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
5.2
|
|
October 28, 2017 - November 24, 2017
|
0.3
|
|
|
$
|
106.29
|
|
|
0.3
|
|
|
4.9
|
|
November 25, 2017 - December 29, 2017
|
0.2
|
|
|
$
|
111.18
|
|
|
0.2
|
|
|
4.7
|
|
Total
|
0.5
|
|
|
$
|
108.16
|
|
|
0.5
|
|
|
4.7
|
|
(1)
|
In November 2016, the VMS Board of Directors authorized the repurchase of an additional 8.0 million shares of VMS common stock commencing on January 1, 2017. Share repurchases may be made in the open market, in privately negotiated transactions (including accelerated share repurchase programs), or under Rule 10b5-1 share repurchase plans, and also may be made from time to time or in one or more larger blocks. All shares that were repurchased under the Company's share repurchase programs have been retired.
|
|
|
|
|
VARIAN MEDICAL SYSTEMS, INC.
|
|
|
|
|
(Registrant)
|
|
|
|
|
|
Dated:
|
February 7, 2018
|
By:
|
|
/s/ GARY E. BISCHOPING JR.
|
|
|
|
|
Gary E. Bischoping Jr.
|
|
|
|
|
Senior Vice President and
|
|
|
|
|
Chief Financial Officer
|
|
|
|
|
(Duly Authorized Officer and
|
|
|
|
|
Principal Financial Officer)
|
|
|
Scheme Implementation Deed
|
|
Sirtex Medical Limited
(ABN 35 078 166 122)
Varian Medical Systems, Inc.
|
|
Watson Mangioni Lawyers Pty Limited
Corporate and Commercial Lawyers
Level 23, 85 Castlereagh Street
SYDNEY NSW 2000
Tel: (02) 9262 6666
Fax: (02) 9262 2626
Email:
mail@wmlaw.com.au
Ref: CSC 217 7345
|
1.
|
Definitions and Interpretation
|
1
|
|
|
|
2.
|
Agreement to Proceed with the Transaction
|
8
|
|
|
|
3.
|
Conditions Precedent and Pre-implementation Steps
|
8
|
|
|
|
4.
|
Transaction Steps
|
12
|
|
|
|
5.
|
Implementation
|
13
|
|
|
|
6.
|
Representations and Warranties
|
18
|
|
|
|
7.
|
Releases
|
19
|
|
|
|
8.
|
Public Announcements
|
20
|
|
|
|
9.
|
Exclusivity
|
21
|
|
|
|
10.
|
Reimbursement Fees
|
23
|
|
|
|
11.
|
Termination
|
27
|
|
|
|
12.
|
Confidentiality
|
28
|
|
|
|
13.
|
GST
|
28
|
|
|
|
14.
|
Duty, Costs and Expenses
|
29
|
|
|
|
15.
|
Notices
|
29
|
|
|
|
16.
|
General
|
31
|
|
|
|
Annexure A
|
Indicative Timetable
|
|
|
|
|
Annexure B
|
Scheme of Arrangement
|
|
|
|
|
Annexure C
|
Deed Poll
|
|
1.
|
Sirtex Medical Limited
(ABN 35 078 166 122) of Level 33, 101 Miller Street, North Sydney NSW 2060, Australia (
Sirtex
);
|
2.
|
Varian Medical Systems, Inc.
of
3100 Hansen Way, Palo Alto, CA 94304-1038, United States
(
Bidder
).
|
A.
|
Sirtex and the Bidder have agreed to propose and implement a scheme of arrangement under Part 5.1 of the Corporations Act between Sirtex and its shareholders.
|
B.
|
At the request of the Bidder, Sirtex has agreed to propose the Scheme and issue the Scheme Booklet.
|
(a)
|
a financier to the entity in connection with the Transaction; or
|
(b)
|
a financial, corporate, legal, technical or other expert adviser or consultant, who provides advisory or consultancy services in a professional capacity in the ordinary course of its business and has been engaged in that capacity in connection with the Transaction by the entity.
|
(a)
|
Todd Hayward v Sirtex Medical Limited (File number: VID91/2017) filed in the Victorian Registry of the Federal Court of Australia on 9 February 2017; and
|
(b)
|
Pawel Kuterba v Sirtex Medical Limited (ACN 78 166 122) (File number: VID1375/2017) filed in the Victorian Registry of the Federal Court of Australia on 15 December 2017,
|
(1)
|
the business or property of the subsidiary contributes more than 20% of the consolidated net profit after tax of Sirtex; or
|
(2)
|
the business or property of the subsidiary represents more than 20% of the total consolidated assets of the Sirtex.
|
(a)
|
it ceases, suspends, or threatens to cease or suspend the conduct of all or a substantial part of its business or disposes of or threatens to dispose of all or a substantial part of its assets;
|
(b)
|
it stops or suspends or threatens to stop or suspend payment of all or a class of its debts;
|
(c)
|
it is, or under legislation is presumed or taken to be, insolvent (other than as the result of a failure to pay a debt or claim the subject of a good faith dispute);
|
(d)
|
it has an administrator, controller or similar officer appointed, or any step preliminary to the appointment of such an officer is taken;
|
(e)
|
an application or an order is made, proceedings are commenced, a resolution is passed or proposed in a notice of meeting, an application to a court or other steps are taken for:
|
(i)
|
its winding up, dissolution or administration; or
|
(ii)
|
it entering into an arrangement, compromise or composition with or assignment for the benefit of its creditors or a class of them,
|
(f)
|
any of:
|
(i)
|
a receiver, receiver and manager, administrative receiver or similar officer is appointed to;
|
(ii)
|
a security interest becomes enforceable or is enforced over; or
|
(iii)
|
a distress, attachment or other execution is levied or enforced or applied for over,
|
(g)
|
anything analogous to anything referred to in the above paragraphs, or which has substantially similar effect, occurs with respect to it, including under any foreign law.
|
(a)
|
a diminution in the consolidated net assets of the Sirtex Group (calculated on the basis of AIFRS as at the date of this deed) of at least $25 million compared to the consolidated net assets of the Sirtex Group as at 31 December 2017; or
|
(b)
|
a permanent and recurring diminution in the annual consolidated earnings before interest expense, tax, depreciation and amortisation and significant and non-recurring items of the Sirtex Group of at least $10 million,
|
(c)
|
required or permitted by this deed or the Scheme (including those comprising, or undertaken pursuant to, the settlement of any Class Action in compliance with clause 5.3(a)(x));
|
(d)
|
which do not relate specifically to the Sirtex Group and which are beyond the control of the Sirtex Group, including those that arise from:
|
(i)
|
changes in exchange rates or interest rates;
|
(ii)
|
general economic, political, regulatory or business conditions in Australia or elsewhere; or
|
(iii)
|
changes to accounting standards or laws in Australia or elsewhere,
|
(e)
|
to the extent Disclosed (including the Class Actions and potential damages payable under them and the costs to be incurred by Sirtex in relation to the Transaction); or
|
(f)
|
to the extent any losses or liabilities arising from such event, occurrence or matter are covered by insurance which Sirtex’s insurers have agreed to pay.
|
(a)
|
any approval, consent, authorisation, registration, filing, lodgement, permit, franchise, agreement, notarisation, certificate, permission, licence, direction, declaration, authority or exemption from, by or with a Government Agency; or
|
(b)
|
in relation to anything that would be fully or partly prohibited or restricted by law if a Government Agency intervened or acted in any way within a specified period after lodgement, filing, registration or notification, the expiry of that period without notification.
|
(i)
|
gives the Bidder written advice, which is unconditional or subject only to conditions that are acceptable to the Bidder acting reasonably, that the Commonwealth Government does not object under FATA or its foreign investment policy to the Transaction; or
|
(ii)
|
is or, by passage of time, becomes precluded from making an order under FATA in respect of the Transaction, and remains so precluded until that time;
|
(i)
|
all applicable waiting periods (and any extensions thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expire or are otherwise terminated;
|
(ii)
|
the German Federal Cartel Office confirms that does not object to, or does not propose to intervene in, the Transaction pursuant to the German Act Against Restraints of Competition (Gesetz gegen Wettbewerbsbeschränkungen);
|
(i)
|
use reasonable endeavours to procure that the Conditions Precedent in clauses 3.1(a), 3.1(d), 3.1(e) and 3.1(f) are satisfied; and
|
(ii)
|
provide reasonable assistance in satisfying the other Conditions Precedent and ensure that there is no occurrence within the control of a member of the Bidder Group or the Sirtex Group (as the context requires) that would prevent any Condition Precedent being satisfied.
|
(i)
|
consult and co-operate fully with the other party in relation to the satisfaction of the Conditions Precedent, including in relation to all material communications with Government Agencies in relation to Regulatory Approvals;
|
(ii)
|
promptly provide to the other party all material communications with Government Agencies in relation to Regulatory Approvals;
|
(iii)
|
promptly notify the other if it becomes aware that any Condition Precedent has been satisfied; and
|
(iv)
|
promptly notify the other of any failure to satisfy a Condition Precedent or of any fact or circumstance that will result in a Condition Precedent becoming incapable of being satisfied or that may result in a Condition Precedent not being satisfied in accordance with its terms (having regard to the obligations of the parties under this clause).
|
(i)
|
Sirtex must provide the Bidder with all information reasonably requested in connection with the Bidder's applications for each Regulatory Approval referred to in clauses 3.1(b) and 3.1(c); and
|
(ii)
|
the Bidder must consult with Sirtex, and Sirtex must consult with the Bidder, as applicable, in relation to the submission of and progress of obtaining each Regulatory Approval referred to in clauses 3.1(b) and 3.1(c).
|
(i)
|
give the Court on the Second Court Date a certificate confirming (in respect of matters within its knowledge) whether or not the Conditions Precedent (other than the Condition Precedent in clause 3.1(f)) have been satisfied or waived; and
|
(ii)
|
give the other a draft of its certificate by 5pm on the Business Day before the Second Court Date.
|
(i)
|
the Bidder must promptly apply for all relevant Regulatory Approvals contemplated by the Conditions Precedent in clauses 3.1(b) and 3.1(c) and promptly provide a copy of all such applications and associated correspondence to Sirtex (provided that any commercially sensitive information may be redacted from the copies provided);
|
(ii)
|
each party must take all steps it is responsible for as part of the applicable approval or consent process in respect of the relevant Regulatory Approvals, including responding to requests for information at the earliest practicable time;
|
(iii)
|
each party acknowledges and agrees that the other party has the right to be represented and make submissions at any meeting with any Regulatory Authority relating to a Regulatory Approval;
|
(iv)
|
each party must consult with the other party in advance in relation to all material communications (whether written or oral, and whether direct or via a Representative) with any Government Agency relating to any Regulatory Approval and, without limitation:
|
(A)
|
provide the other party with drafts of any material written communications to be sent to a Government Agency and take any reasonable comments made by the other party into account in good faith when making any amendments; and
|
(B)
|
provide copies of any material written communications sent to or received from a Government Agency to the other party promptly upon despatch or receipt (as the case may be), in each case to the extent it is reasonable, and not in breach of any law or requirement of the relevant Government Agency, to do so; and
|
(v)
|
subject to the terms of the applicable Condition Precedent, each party must promptly offer to the relevant Government Agency, and agree or accept, all undertakings, commitments and conditions reasonably necessary or appropriate in order to obtain the approval, confirmation or consent (as the case may be) as soon as possible, unless it would be unreasonable to do so and, without limiting this clause 3.3(a)(v), in relation to the confirmation referred to in clause 3.1(c)(ii), the Bidder must offer to the relevant Government Agency, and agree to accept, all undertakings, commitments and conditions reasonably necessary or appropriate in order to obtain the confirmation at phase 1 (or equivalent).
|
(i)
|
clause 3.3(a)(ii); and
|
(ii)
|
clause 3.2(a),
|
(i)
|
the Scheme has not become Effective by the End Date; or
|
(i)
|
a breach of this deed (including clause 3.2) by that party; or
|
(ii)
|
a deliberate act or omission of that party.
|
(i)
|
other than the Bidder Information and the Independent Expert’s Report, the Scheme Booklet has been prepared by Sirtex and is the responsibility of Sirtex, and that no Bidder Party assumes any responsibility for the accuracy or completeness of the Scheme Booklet (other than the Bidder Information); and
|
(ii)
|
the Bidder Information has been provided by Bidder and is the responsibility of Bidder, and that no Sirtex Party assumes any responsibility for the accuracy or completeness of the Bidder Information.
|
(i)
|
providing to the Bidder successive drafts of the Scheme Booklet and allowing the Bidder a reasonable opportunity to review and comment on those draft documents before lodgement of the Scheme Booklet with ASIC;
|
(ii)
|
considering in good faith all comments made by the Bidder and its Representatives for the purpose of amending the Scheme Booklet; and
|
(iii)
|
obtaining the Bidder’s consent to the inclusion of the Bidder Information (including in respect of the form and context in which the Bidder Information appears in the Scheme Booklet);
|
(c)
|
information
: prepare and promptly provide to the Bidder any information regarding the Sirtex Group that the Bidder reasonably requires to prepare the Bidder Information for inclusion in the Scheme Booklet;
|
(i)
|
an indication of intent letter stating that it does not intend to make any submissions at the Court hearing on the First Court Date or otherwise object to the Scheme; and
|
(ii)
|
a statement under section 411(17)(b) of the Corporations Act that ASIC has no objection to the Scheme;
|
(i)
|
confirm in writing to Sirtex that the Bidder Information in the form and context in which it appears in the Scheme Booklet is not misleading or deceptive in any material respect and does not contain any material omission; or
|
(ii)
|
provide to Sirtex the changes required to ensure that the Bidder Information in the form and context in which it appears in the Scheme Booklet is not misleading or deceptive in any material respect and does not contain any material omission;
|
(i)
|
of new information which, were it known at the time of despatch, should have been included in any Bidder Information provided previously to Sirtex; or
|
(ii)
|
that any part of the Bidder Information provided previously to Sirtex is misleading or deceptive in any material respect (whether by omission or otherwise),
|
(i)
|
is required or permitted by this deed or the Scheme;
|
(ii)
|
has been Disclosed;
|
(iii)
|
is required by law or a Government Agency;
|
(iv)
|
has been consented to in writing by the Bidder (and the Bidder will consider in good faith, acting reasonably, any request for consent from Sirtex where Sirtex has provided reasonable details of the matter (including any material terms) in writing to the Bidder and must not unreasonably withhold or delay its consent to any such request); or
|
(v)
|
conduct their businesses in the ordinary course consistent with business plans and budgets Disclosed and otherwise in a manner generally consistent with the manner in which such businesses have been conducted in the 12 months prior to the date of this deed;
|
(vi)
|
use all reasonable endeavours to maintain and preserve their relationships with customers, suppliers, Government Agencies, landlords, licensors, licensees and others having business dealings with them, including by using reasonable endeavours to obtain their consent to the Transaction to the extent required under any material agreement with such third parties; and
|
(vii)
|
do not enter any lines of business or other activities in which members of the Sirtex Group are not engaged at the date of this deed;
|
(viii)
|
conduct their businesses and operations substantially in accordance with all applicable laws and regulations;
|
(ix)
|
where reasonably requested, consult with the Bidder and provide updates as to the progress of their business and operations;
|
(x)
|
do not settle the Class Actions, or any part of them, or take any other step that compromises the members of the Sirtex Group’s rights in respect of the Class Actions;
|
(xi)
|
do not incur any additional financial indebtedness by way of borrowings and other financial facilities including operating and finance leases (except for draw-downs on existing banking facilities or utilisation of existing securitisation programs) or guarantee or indemnify the obligations of any person other than a member of the Sirtex Group, other than in the usual and ordinary course of business and consistent with past practice; and
|
(xii)
|
do not make any material change to the terms of employment of any director, executive or senior manager (except as required by law, publicly disclosed prior to the date of this deed or as provided in an existing contract in place as at the date of this deed).
|
(i)
|
the Board unanimously recommends (including in the Scheme Booklet) that, in the absence of a superior proposal and subject to the Independent Expert concluding that the Transaction is in the best interests of Sirtex Shareholders, Sirtex Shareholders vote in favour of the Scheme at the Scheme Meeting; and
|
(ii)
|
the Scheme Booklet will include a statement by the Board to that effect and to the effect that each director of Sirtex will, in the absence of a superior proposal and subject to the Independent Expert concluding that the Transaction is in the best interests of Sirtex Shareholders, vote (or procure the voting) of all Sirtex Shares held or controlled by them in favour of the Scheme at the Scheme Meeting.
|
(i)
|
the Independent Expert concludes in the Independent Expert’s Report (or any update or variation to that report) that the Scheme is not in the best interests of Sirtex Shareholders, or adversely changes its previously given opinion in the Independent Expert’s Report (or any update or variation to that report) that the Scheme is in the best interests of Sirtex Shareholders;
|
(ii)
|
Sirtex receives a Competing Proposal and the Board, acting in good faith, determines (after consultation with its financial advisers) that the Competing Proposal constitutes a Superior Proposal; or
|
(iii)
|
that director, acting in good faith, determines (after taking written advice from Sirtex’s or their own external financial and legal advisers) that a failure by them or the Board to change, withdraw or modify such recommendation or make a recommendation or statement that is inconsistent with it would be reasonably likely to constitute a breach of their fiduciary or statutory obligations.
|
(i)
|
Sirtex any right or power to give undertakings to the Court for or on behalf of the Bidder (or, if applicable, the Bidder Nominee); or
|
(ii)
|
the Bidder (or, if applicable, the Bidder Nominee) any right or power to give undertakings to the Court for or on behalf of Sirtex, in each case, without the relevant party’s written consent.
|
(i)
|
are required to be done under this deed or the Scheme;
|
(ii)
|
took place with the prior written consent of the Bidder;
|
(iii)
|
have been Disclosed; or
|
(iv)
|
as at the date of this deed are within the actual knowledge of Bidder or the Bidder’s Representatives.
|
(i)
|
any breach of any representation, covenant or warranty of Sirtex in this deed;
|
(ii)
|
any disclosure made by any Sirtex Party that contains any statement which is false or misleading whether in content or by omission, except to the extent that the relevant Sirtex Party has not acted in good faith or has engaged in wilful misconduct.
|
(i)
|
any breach of any representation, covenant or warranty of the Bidder in this deed;
|
(ii)
|
any disclosure made by any Bidder Party that contains any statement which is false or misleading whether in content or by omission, except to the extent that the relevant Bidder Party has not acted in good faith or has engaged in wilful misconduct.
|
(i)
|
for a period of not less than 7 years from the Implementation Date, ensure that the constitutions of Sirtex and each other member of the Sirtex Group continue to contain such rules as are contained in those constitutions at the date of this deed that provide for each company to indemnify each of its current and former directors and officers against any liability incurred by that person in their capacity as a director or officer of the company to any person other than a member of the Sirtex Group; and
|
(ii)
|
procure that Sirtex and each other member of the Sirtex Group complies with any deeds of indemnity, access and insurance made by them in favour of their respective directors and officers from time to time and, without limiting the foregoing, ensure that directors’ and officers’ run-off insurance cover for those directors and officers is maintained (with the same level of cover, and on the same terms, as maintained by the Sirtex Group at the date of this deed or with a higher level of cover or on terms more favourable to those directors and officers) for a period of not less than 7 years from the retirement date of each director and officer.
|
(a)
|
a unanimous recommendation by the directors of Sirtex to Sirtex Shareholders consistent with that set out in clause 5.5(a)(i); and
|
(i)
|
the fact that such an approach has been made;
|
(ii)
|
the identity of the Third Party who has made the approach, and the identity of the person making or proposing any Competing Proposal; and
|
(iii)
|
all material terms of any Competing Proposal (to the extent known by Sirtex),
|
(i)
|
completes in all material respects a transaction of the kind referred to in paragraph (b), (c) or (d) of the definition of Competing Proposal; or
|
(ii)
|
without limiting clause 10.2(a)(i) above, has a relevant interest in at least 50% of Sirtex Shares,
|
(i)
|
a majority of the members of the Board make a public statement withdrawing or adversely changing or modifying their recommendation that Sirtex Shareholders vote in favour of the Scheme at the Scheme Meeting or their statement that they will vote (or procure the voting) of all Sirtex Shares held or controlled by them in favour of the Scheme at the Scheme Meeting (including by attaching qualifications to such recommendation or statement) or make a recommendation or statement that is inconsistent with such recommendation or statement; or
|
(ii)
|
without limiting the foregoing, a majority of members of the Board make a public statement indicating that they no longer support the Scheme or that they support a Competing Proposal,
|
(iii)
|
due to the Independent Expert concluding in the Independent Expert’s Report (or any update or variation to that report) that the Scheme is not in the best interests of Sirtex Shareholders, or adversely changing its previously given opinion in the Independent Expert’s Report (or any update or variation to that report) that the Scheme is in the best interests of Sirtex Shareholders (except in circumstances where the Independent Expert reaches that conclusion or makes that change as a result of a Competing Proposal having been announced or made public); or
|
(iv)
|
in circumstances where Sirtex is entitled to terminate this deed in accordance with clause 11.1(a) or clause 11.1(b);
|
(i)
|
no amount is payable by any party under those clause; and
|
(ii)
|
if any amount has already been paid under those clauses it must be refunded by the recipient within 20 Business Days after the Scheme becomes Effective.
|
(i)
|
the maximum liability of a party to the other party under or in connection with this deed including in respect of any breach of this deed will be the Reimbursement Fee and in no event will the aggregate liability of a party under or in connection with a breach of this deed exceed an amount equal to the Reimbursement Fee; and
|
(ii)
|
the payment by a party to the other party of the Reimbursement Fee represents the sole and absolute amount of liability of that party to the other party under or in connection with this deed and no further damages, fees, expenses or reimbursements of any kind will be payable by that party to the other party in connection with this deed.
|
(i)
|
prevents a party (in its own right or as agent or trustee on behalf of any person contemplated by this deed) from seeking orders from a court of competent jurisdiction for the specific performance by the other party of any obligations under this deed; or
|
(ii)
|
extinguishes or limits the liability of a party for any breach of this deed arising from criminal acts or fraud by the other party or a Representative of the other party.
|
(i)
|
is unlawful or would if performed be, unlawful;
|
(ii)
|
involves a breach of the duties of the Board; or
|
(iii)
|
constitutes unacceptable circumstances within the meaning of the Corporations Act,
|
(i)
|
Sirtex has given written notice to the Bidder setting out the relevant circumstances and stating an intention to terminate this deed or to allow the Scheme to lapse;
|
(ii)
|
the relevant breach or circumstances have not been remedied within 10 Business Days after such notice is given (or any shorter period ending at 8am on the Second Court Date); and
|
(iii)
|
the relevant breach of the Bidder Representations and Warranties is material in the context of the scheme taken as a whole;
|
(i)
|
the Bidder has given written notice to Sirtex setting out the relevant circumstances and stating an intention to terminate this deed or to allow the Scheme to lapse;
|
(ii)
|
the relevant breach or circumstances have not been remedied within 10 Business Days after such notice is given (or any shorter period ending at 8am on the Second Court Date); and
|
(iii)
|
the relevant breach of the Sirtex Representations and Warranties is material in the context of the Scheme taken as a whole;
|
(i)
|
delivered by hand to the address of the party referred to in clause 15.3;
|
(ii)
|
sent by regular ordinary post (airmail if sent from one country to another) to the address of the party referred to in clause 15.3; or
|
(iii)
|
sent by email to the email address of the party referred to in clause 15.3.
|
Name:
|
Sirtex Medical Limited
|
Address:
|
Level 33, 101 Miller Street, North Sydney NSW 2060, Australia
|
Attention:
|
Andrew McLean
|
Email:
|
andrew.mclean@sirtex.com
|
Name:
|
Watson Mangioni
|
Address:
|
Level 23, 85 Castlereagh Street, Sydney NSW 2000, Australia
|
Attention:
|
Chris Clarke
|
Email:
|
cclarke@wmlaw.com.au
|
Name:
|
Varian Medical Systems, Inc.
|
Address:
|
3100 Hansen Way, Palo Alto, CA 94304-1038, United States
|
Attention:
|
Mike Dunn
|
Email:
|
Mike.Dunn@varian.com
|
Name:
|
Norton Rose Fulbright
|
Address:
|
Level 18, Grosvenor Place, 225 George Street, Sydney NSW 2000
|
Attention:
|
Shaun Clyne / Jeremy Wickens
|
Email:
|
shaun.clyne@nortonrosefulbright.com / jeremy.wickens@nortonrosefulbright.com
|
(i)
|
when the sender receives an automated message confirming delivery; or
|
(ii)
|
4 hours after the time sent (as recorded on the device from which the sender sent the email) unless the sender receives an automated message that delivery failed,
|
Security
|
Number on issue at date of this deed
|
Sirtex Shares
|
55,773,045
|
Sirtex Rights
|
825,954, comprising:
•
129,744 Sirtex Rights issued in CY15 (with a vesting date of 30 June 2018);
•
206,686 Sirtex Rights issued in CY16 (with a vesting date of 30 June 2019); and
•
489,524 Sirtex Rights issued in CY17 (with a vesting date of 30 June 2020).
|
SIGNED, SEALED & DELIVERED by
Sirtex Medical Limited
(ABN 35 078 166 122)
in accordance with section 127 of the Corporations Act:
|
)
)
)
)
)
|
|
/s/ John A. Eady
|
|
/s/ Andrew McLean
|
Director/Secretary
|
|
Director
|
John A. Eady
|
|
Andrew McLean
|
Name (please print)
|
|
Name (please print)
|
SIGNED, SEALED & DELIVERED by
Varian Medical Systems, Inc.
by its duly authorised representative in the presence of:
|
)
)
)
)
|
|
/s/ Gary E. Bischoping
|
|
/s/ Dow R. Wilson
|
Witness
|
|
Authorised Representative
|
Gary E. Bischoping
|
|
Dow R. Wilson
|
Name (please print)
|
|
Name (please print)
|
Event
|
|
Target date
|
Announcement
|
|
30 January 2018
|
First complete draft of Scheme Booklet (including expert’s report)
|
|
5 March 2018
|
Scheme Booklet complete and provided to ASIC
|
|
12 March 2018
|
First Court hearing
|
|
29 March 2018
|
Mailing of Scheme Booklet complete
|
|
5 April 2018
|
Scheme Meeting
|
|
7 May 2018
|
Second Court hearing
|
|
9 May 2018
|
Effective Date
|
|
10 May 2018
|
Record Date
|
|
17 May 2018
|
Implementation Date
|
|
24 May 2018
|
|
|
Scheme of Arrangement
Dated
|
|
Sirtex Medical Limited
(ABN 35 078 166 122)
Scheme Shareholders
|
|
Watson Mangioni Lawyers Pty Limited
Corporate and Commercial Lawyers
Level 23, 85 Castlereagh Street
SYDNEY NSW 2000
Tel: (02) 9262 6666
Fax: (02) 9262 2626
Email:
mail@wmlaw.com.au
Ref: CSC 217 7345
|
1.
|
Definitions and Interpretation
|
|
2.
|
Preliminary
|
|
3.
|
Conditions Precedent
|
|
4.
|
Scheme
|
|
5.
|
Implementation of Scheme
|
|
6.
|
Scheme Consideration
|
|
7.
|
Dealings in Scheme Shares
|
|
8.
|
Quotation of Sirtex Shares
|
|
9.
|
General Scheme Provisions
|
|
1.
|
Sirtex Medical Limited
(ABN 35 078 166 122) of Level 33, 101 Miller Street, North Sydney NSW 2060, Australia (
Sirtex
);
|
2.
|
Each person registered as a holder of fully paid ordinary shares in Sirtex as at the Record Date (
Scheme Shareholders
).
|
1.
|
Definitions and Interpretation
|
1.1
|
Definitions
|
1.2
|
Interpretation
|
(a)
|
words importing the singular include the plural and vice versa;
|
(b)
|
words importing a gender include any gender;
|
(c)
|
other parts of speech and grammatical forms of a word or phrase defined in this Scheme have a corresponding meaning;
|
(d)
|
a reference to a person includes an individual, the estate of an individual, a corporation, an authority, an association or a joint venture, a partnership, a trust and any Government Agency;
|
(e)
|
a reference to a clause, party, attachment, exhibit or schedule is a reference to a clause of, and a party, attachment, exhibit and schedule to this Scheme, and a reference to this Scheme includes any attachment, exhibit and schedule;
|
(f)
|
a reference to a statute, regulation, proclamation, ordinance or by law includes all statutes, regulations, proclamations, ordinances or by laws amending, consolidating or replacing it, whether passed by the same or another Government Agency with legal power to do so, and a reference to a statute includes all regulations, proclamations, ordinances and by laws issued under that statute;
|
(g)
|
a reference to any document (including this Scheme) is to that document as varied, novated, ratified or replaced from time to time;
|
(h)
|
the word “includes” in any form is not a word of limitation;
|
(i)
|
a reference to “$”, “A$” or “dollar” is to Australian currency;
|
(j)
|
a reference to any time is, unless otherwise indicated, a reference to the time in Sydney, New South Wales, Australia;
|
(k)
|
a period of time dating from a given day or the day of an act or event, is to be calculated exclusive of that day;
|
(l)
|
a day is to be interpreted as the period of time commencing at midnight and ending 24 hours later;
|
(m)
|
a reference to “associate”, “control” (by an entity of another entity), “officer”, “related body corporate”, “subsidiary”, “relevant interest” or “voting power” is to that term as defined in the Corporations Act;
|
(n)
|
a reference to the ASX Listing Rules includes any variation, consolidation or replacement of these rules and is to be taken to be subject to any waiver or exemption granted to the compliance of those rules by a party.
|
1.3
|
Business Day
|
(i)
|
a public company limited by shares;
|
(ii)
|
incorporated in Australia and registered in Western Australia; and
|
(iii)
|
admitted to the official list of the ASX and Sirtex Shares are officially quoted on the stock market conducted by ASX.
|
2.2
|
The Bidder
|
2.3
|
Bidder Nominee
|
(a)
|
Pursuant to clause 2.2 of the Scheme Implementation Deed, the Bidder may nominate a wholly owned Subsidiary of the Bidder (
Bidder Nominee
) to pay the Scheme Consideration and to which the Scheme Shares are to be transferred in accordance with clause 5 of this Scheme.
|
(b)
|
If the Bidder nominates a Bidder Nominee, then clause 2.2 of the Scheme Implementation Deed provides that:
|
(i)
|
the Bidder must procure that the Bidder Nominee complies with the Scheme Implementation Deed as if the Bidder Nominee were a party to it in place of the Bidder; and
|
(ii)
|
any such nomination will not relieve the Bidder of its obligations under the Scheme Implementation Deed, including the obligation to pay (or procure the payment by Bidder Nominee of) the Scheme Consideration as contemplated by the terms of this Scheme.
|
2.4
|
If Scheme becomes Effective
|
(a)
|
in consideration of the transfer of each Scheme Share to the Bidder (or if applicable, the Bidder Nominee), the Bidder will provide (or procure the Bidder Nominee to provide) the Scheme Consideration to Sirtex on behalf of each Scheme Shareholder in accordance with the terms of this Scheme;
|
(b)
|
all Scheme Shares will be transferred to the Bidder (or if applicable, the Bidder Nominee) on the Implementation Date; and
|
(c)
|
Sirtex will enter the name of the Bidder (or if applicable, the Bidder Nominee) in the Share Register in respect of all Scheme Shares transferred to the Bidder (or if applicable, the Bidder Nominee) in accordance with the terms of this Scheme.
|
(a)
|
as at 8am on the Second Court Date, neither the Deed Poll nor the Scheme Implementation Deed have been terminated in accordance with their terms;
|
(b)
|
all of the conditions precedent in clause 3.1 of the Scheme Implementation Deed having been satisfied or waived (other than the condition precedent in clause 3.1(c) of this Scheme) in accordance with the terms of the Scheme Implementation Deed by 8am on the Second Court Date;
|
(c)
|
the Court having approved this Scheme, with or without any modification or condition, pursuant to section 411(4)(b) of the Corporations Act, and if applicable, Sirtex and the Bidder having accepted in writing any modification or condition made or required by the Court under section 411(6) of the Corporations Act; and
|
(d)
|
the coming into effect, pursuant to section 411(10) of the Corporations Act, of the orders of the Court made under section 411(4)(b) of the Corporations Act (and, if applicable, section 411(6) of the Corporations Act) in relation to this Scheme.
|
(a)
|
Each of Sirtex and the Bidder must provide to the Court on the Second Court Date a certificate confirming (in respect of matters within their knowledge) whether or not all of the conditions precedent set out in clause 3.1 of this Scheme (other than the conditions precedent in clause 3.1(c) and clause 3.1(d) of this Scheme) have been satisfied or waived as at 8am on the Second Court Date.
|
(b)
|
The certificates referred to in clause 3.3(a) will constitute conclusive evidence of whether the conditions precedent referred to in clause 3.1 of this Scheme (other than the conditions precedent in clause 3.1(c) and 3.1(d) of this Scheme) have been satisfied or waived as at 8am on the Second Court Date.
|
(a)
|
the Scheme Implementation Deed or the Deed Poll is terminated in accordance with its terms before the Scheme becomes Effective; or
|
(a)
|
the Scheme Shares, together with all rights and entitlements attaching to the Scheme Shares as at the Implementation Date, will be transferred to the Bidder (or if applicable, the Bidder Nominee) without the need for any further act by any Scheme Shareholder (other than acts performed by Sirtex as attorney and agent for Scheme Shareholders under clause 9.1 of this Scheme) by:
|
(iv)
|
Sirtex delivering to the Bidder (or if applicable, the Bidder Nominee) a duly completed and executed Scheme Share Transfer executed on behalf of the Scheme Shareholders; and
|
(v)
|
the Bidder (or if applicable, the Bidder Nominee) duly executing the Scheme Share Transfer, attending to the stamping of the Scheme Share Transfer (if required) and delivering it to Sirtex for registration; and
|
(b)
|
as soon as practicable after receipt of the duly executed Scheme Share Transfer, Sirtex must enter, or procure the entry of, the name of the Bidder (or if applicable, the Bidder Nominee) in the Share Register in respect of all Scheme Shares transferred to the Bidder (or if applicable, the Bidder Nominee) in accordance with the terms of this Scheme.
|
(a)
|
all their Scheme Shares (including any rights and entitlements attaching to those Scheme Shares) transferred to the Bidder (or if applicable, the Bidder Nominee) under the Scheme will, as at the date of the transfer, be fully paid and free from all Encumbrances; and
|
(b)
|
they have full power and capacity to sell and to transfer their Scheme Shares (including any rights and entitlements attaching to those Scheme Shares) to the Bidder (or if applicable, the Bidder Nominee) under the Scheme.
|
(a)
|
irrevocably appoints Sirtex as attorney and agent (and directs Sirtex in such capacity) to appoint the Bidder (or if applicable, the Bidder Nominee) and each of its directors from time to time (jointly and each of them individually) as its sole proxy and where applicable, corporate representative, to attend shareholders’ meetings, exercise the votes attaching to Sirtex Shares registered in its name and sign any shareholders resolution, and no Scheme Shareholder may itself attend or vote at any of those meetings or sign any resolutions, whether in person, by proxy or by corporate representative (other than pursuant to this clause 5.8(a));
|
(b)
|
must take all other actions in the capacity of the registered holder of Sirtex Shares as the Bidder (or if applicable, the Bidder Nominee) reasonably directs;
|
(c)
|
acknowledges and agrees that in exercising the powers referred to in this clause 5.8(a), the Bidder and any director, officer or agent nominated under this clause 5.8(a) may act in the best interests of the Bidder as the intended registered holder of the Scheme Shares.
|
(a)
|
The Bidder must (pursuant to its obligations under the Deed Poll), by no later than the Business Day before the Implementation Date, deposit (or procure the deposit) in cleared funds the aggregate amount of the Scheme Consideration payable to all Scheme Shareholders into the Trust Account.
|
(b)
|
On the Implementation Date, subject to receipt of the Scheme Consideration from or on behalf of the Bidder (or the Bidder Nominee) in accordance with clause 6.1(a) of this Scheme, Sirtex
|
(i)
|
where a Scheme Shareholder has, before the Record Date, made an election in accordance with the requirements of the Share Register to receive dividend payments from Sirtex by electronic funds transfer to a bank account nominated by the Scheme Shareholder, paying, or procuring the payment of, the relevant amount in Australian currency by electronic means in accordance with that election; or
|
(ii)
|
whether or not a Scheme Shareholder has made an election referred to in clause 6.1(b)(i), dispatching, or procuring the dispatch of, a cheque drawn on an Australian bank in Australian currency for the relevant amount to the Scheme Shareholder by pre-paid ordinary post (or, if the address of the Scheme Shareholder in the Share Register is outside Australia, by pre-paid airmail post) to their Registered Address at the Record Date, such cheque being drawn in the name of the Scheme Shareholder (or in the case of joint holders, in accordance with clause 6.5).
|
(c)
|
If there is any surplus in the amount held by Sirtex in the Trust Account, that surplus must be paid by Sirtex to the Bidder following the satisfaction of Sirtex’s obligations under this clause.
|
6.2
|
Cancellation and re-issue of cheques
|
(ii)
|
has not been presented for payment within 6 months after the date on which the cheque was sent.
|
(b)
|
During the period of one year commencing on the Implementation Date, on request from a Scheme Shareholder (which request may not be made until the date which is 5 Business Days after the Implementation Date), Sirtex must reissue a cheque that was previously cancelled under this clause 6.2.
|
(c)
|
Sirtex must maintain appropriate records of all payments made in accordance with this clause 6 of this Scheme, including (amongst other things) the amounts paid (including the method of payment in accordance with clause 6.1(b)), the persons paid and any cancelled cheques pursuant to this clause 6.2.
|
(a)
|
The
Unclaimed Money Act
1995 (NSW) will apply in relation to any Scheme Consideration which becomes “unclaimed money” (as defined in section 7 of the
Unclaimed Money Act
1995 (NSW)).
|
(b)
|
Any interest or other benefit accruing from unclaimed Scheme Consideration will be to the benefit of the Bidder.
|
(a)
|
which requires payment to a third party of a sum in respect of Scheme Shares held by a particular Scheme Shareholder, which would otherwise be payable to that Scheme Shareholder in accordance with clause 6.1 of this Scheme, then Sirtex shall procure that payment is made in accordance with that order; or
|
(b)
|
which would prevent Sirtex from dispatching payment to any particular Scheme Shareholder in accordance with clause 6.1 of this Scheme, or such payment is otherwise prohibited by applicable law, Sirtex will be entitled to retain an amount, in Australian dollars, equal to the number of Scheme Shares held by that Scheme Shareholder multiplied by the Scheme Consideration until such time as payment in accordance with clause 6.1 of this Scheme is permitted by law.
|
(a)
|
If this Scheme becomes Effective, a holder of Scheme Shares (and any person claiming through that holder) must not dispose of or purport or agree to dispose of any Scheme Shares or any interest in them after the Effective Date in any way except as set out in this Scheme and any such disposal will be void and of no legal effect whatsoever.
|
(b)
|
Sirtex will not accept for registration or recognise for any purpose any transmission, application or transfer in respect of Scheme Shares received after the Record Date (except a transfer to the Bidder (or if applicable, the Bidder Nominee) pursuant to this Scheme and any subsequent transfer by the Bidder (or if applicable, the Bidder Nominee) or its successors in title) or received prior to the Record Date but not in registrable or actionable form.
|
(a)
|
Suspension of trading on ASX in Sirtex Shares will occur from the close of trading on ASX on the Effective Date.
|
(a)
|
executing any document necessary or expedient to give effect to this Scheme including the Scheme Share Transfer;
|
(b)
|
enforcing the Deed Poll against the Bidder (or if applicable, the Bidder Nominee), and Sirtex accepts such appointment.
|
(a)
|
irrevocably consents to Sirtex and the Bidder (or if applicable, the Bidder Nominee) doing all things necessary or expedient for or incidental to the implementation of this Scheme; and
|
(b)
|
acknowledges that this Scheme binds Sirtex and all Scheme Shareholders (including those who do not attend the Scheme Meeting or do not vote at that meeting or vote against the Scheme at the Scheme Meeting) and, to the extent of any inconsistency and to the extent permitted by law, overrides the constitution of Sirtex.
|
(a)
|
pay all stamp duties, registration fees and similar taxes payable or assessed as being payable in connection with this Scheme or the Deed Poll (including any fees, fines, penalties and interest in connection with those amounts); and
|
(b)
|
indemnify each Scheme Shareholder against any liability incurred by the Scheme Shareholder arising from its failure to comply with clause 9.7(a).
|
(a)
|
If a notice, transfer, transmission application, direction or other communication referred to in this Scheme is sent by post to Sirtex, it will not be taken to be received in the ordinary course of post or on a date and time other than the date and time (if any) on which it is actually received at Sirtex’s registered office or at the office of the Registry.
|
(b)
|
The accidental omission to give notice of the Scheme Meeting or the non-receipt of such a notice by any Sirtex Shareholder shall not, unless so ordered by the Court, invalidate the Scheme Meeting or the proceedings of the Scheme Meeting.
|
(ii)
|
waives, without limitation, any claim or objection based on absence of jurisdiction or inconvenient forum.
|
|
|
Deed Poll
Dated
|
|
Given by
Varian Medical Systems, Inc.
In favour of
Scheme Shareholders
|
1.
|
Definitions and Interpretation
|
|
2.
|
Conditions Precedent and Termination
|
|
3.
|
Performance of Obligations Generally
|
|
4.
|
Scheme Consideration
|
|
5.
|
Representations and Warranties
|
|
6.
|
Continuing Obligations
|
|
7.
|
Notices
|
|
8.
|
General
|
|
A.
|
The directors of Sirtex have resolved that Sirtex should propose the Scheme.
|
Name:
|
Varian Medical Systems, Inc.
|
Address:
|
3100 Hansen Way, Palo Alto, CA 94304-1038, United States
|
Attention:
|
Mike Dunn
|
Email:
|
Mike.Dunn@varian.com
|
Name:
|
Norose Notices Australia Pty Ltd
|
Address:
|
Level 16, ‘Grosvenor Place’, 225 George Street, Sydney, NSW 2000
|
Attention:
|
Shaun Clyne / Jeremy Wickens
|
Email:
|
shaun.clyne@nortonrosefulbright.com / jeremy.wickens@nortonrosefulbright.com
|
SIGNED, SEALED & DELIVERED by
Varian Medical Systems, Inc.
by its duly authorised representative in the presence of:
|
)
)
)
)
|
|
|
|
|
Witness
|
|
Authorized Representative
|
|
|
|
Name (please print)
|
|
Name (please print)
|
1.
|
I have reviewed this Quarterly Report on Form 10-Q of Varian Medical Systems, Inc. (the “registrant”);
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonable likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Dated:
|
February 7, 2018
|
/s/
|
Dow R. Wilson
|
|
|
|
Dow R. Wilson
|
|
|
|
President
|
|
|
|
and Chief Executive Officer
|
1.
|
I have reviewed this Quarterly Report on Form 10-Q of Varian Medical Systems, Inc. (the “registrant”);
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonable likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Dated:
|
February 7, 2018
|
/s/
|
Gary E. Bischoping Jr.
|
|
|
|
Gary E. Bischoping Jr.
|
|
|
|
Senior Vice President and
|
|
|
|
Chief Financial Officer
|
(1)
|
the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
(2)
|
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Dated:
|
February 7, 2018
|
/s/
|
Dow R. Wilson
|
|
|
|
Dow R. Wilson
|
|
|
|
President
|
|
|
|
and Chief Executive Officer
|
(1)
|
the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
(2)
|
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Dated:
|
February 7, 2018
|
/s/
|
Gary E. Bischoping Jr.
|
|
|
|
Gary E. Bischoping Jr.
|
|
|
|
Senior Vice President and
|
|
|
|
Chief Financial Officer
|